var title_f40_59_41904="Traumatic liver laceration";
var content_f40_59_41904=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traumatic liver laceration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography image showing a Grade II lacerations of the liver (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Wesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41904=[""].join("\n");
var outline_f40_59_41904=null;
var title_f40_59_41905="Patient information: Vertigo (a type of dizziness) (The Basics)";
var content_f40_59_41905=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15755\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/48/35589\">",
"         The vestibular system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?40/31/41460\">",
"         Patient information: Dizziness and vertigo (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vertigo (a type of dizziness) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vertigo-a-type-of-dizziness-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1742292300\">",
"      <span class=\"h1\">",
"       What are dizziness and vertigo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Dizziness is a feeling that is hard to describe. It often makes you feel like you are about to fall or pass out. Dizziness can also cause you to feel lightheaded or make it hard for you to walk straight.",
"     </p>",
"     <p>",
"      Many people who feel dizzy have vertigo, a type of dizziness. Vertigo makes you feel like you are spinning, swaying, or tilting, or like the room is moving around you. These feelings come and go, and may last seconds, hours, or days. You may feel worse when you move your head, change positions, cough, or sneeze.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1742292307\">",
"      <span class=\"h1\">",
"       What causes vertigo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common causes of vertigo include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Inner ear problems",
"        </strong>",
"        &mdash; Deep inside the ear, there is a small network of tubes that are filled with fluid. Floating inside that fluid are special calcium deposits. Together, these tubes and deposits make up the &ldquo;vestibular system.&rdquo; This system tells the brain what position the body is in. It also helps keep you balanced (",
"        <a class=\"graphic graphic_figure graphicRef52509 \" href=\"mobipreview.htm?34/48/35589\">",
"         figure 1",
"        </a>",
"        ).",
"        <br/>",
"        <br/>",
"        If the tubes inside your inner ear get swollen, or if they form extra calcium deposits, you can lose your balance and develop vertigo. You can also get vertigo if swelling puts pressure on nerves in the inner ear. Sometimes this swelling is caused by a viral infection.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Head injury",
"        </strong>",
"        &mdash; Head injuries can disturb the inner ear and lead to vertigo.",
"       </li>",
"       <li>",
"        <strong>",
"         Medicines",
"        </strong>",
"        &mdash; Some medicines can damage the inner ear and cause vertigo.",
"       </li>",
"       <li>",
"        <strong>",
"         Migraine headaches",
"        </strong>",
"        &mdash; For reasons doctors do not really understand, migraine headaches can sometimes cause vertigo.",
"       </li>",
"       <li>",
"        <strong>",
"         Brain problems",
"        </strong>",
"        &mdash; Brain problems, such as stroke or multiple sclerosis, can also cause vertigo.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1742292314\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse right away if you have vertigo and:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have a new or severe headache",
"       </li>",
"       <li>",
"        Have a fever higher than 100.4&ordm;F (38&ordm;C)",
"       </li>",
"       <li>",
"        Start to see double or have trouble seeing clearly",
"       </li>",
"       <li>",
"        Have trouble speaking or hearing",
"       </li>",
"       <li>",
"        Have weakness in an arm or leg or your face droops to one side",
"       </li>",
"       <li>",
"        Pass out",
"       </li>",
"       <li>",
"        Have numbness or tingling",
"       </li>",
"       <li>",
"        Have chest pain",
"       </li>",
"       <li>",
"        Cannot stop vomiting",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You should also see your doctor or nurse if you have vertigo that lasts for several minutes or more and you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Are older than 60",
"       </li>",
"       <li>",
"        Had a stroke in the past",
"       </li>",
"       <li>",
"        Are at risk for having a stroke, for example because you have diabetes or you smoke",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have dizziness or vertigo that comes and goes but you do not have any of the problems listed above, make an appointment with your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1742292321\">",
"      <span class=\"h1\">",
"       How is vertigo treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your doctor knows what is causing your vertigo, he or she will probably try to treat that problem directly. For instance, if you have calcium deposits in your inner ear, the doctor might try to get them out by moving your head in a special way.",
"     </p>",
"     <p>",
"      If the doctor does not know what is causing your vertigo, he or she can give you treatments for the symptoms that come with vertigo. For example, the doctor can give you medicines to relieve nausea and vomiting.",
"     </p>",
"     <p>",
"      If your vertigo is really bad, your doctor might also suggest a treatment called &ldquo;balance rehabilitation.&rdquo; This treatment teaches you exercises that can help you cope with your vertigo.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1742292328\">",
"      <span class=\"h1\">",
"       What can I do on my own to deal with my vertigo?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have trouble standing or walking because of vertigo, you are at risk of falling. To reduce the risk of falls, make your home as safe as possible. Get rid of loose electrical cords, clutter, and slippery rugs. Also, make sure that you wear sturdy, non-slip shoes, and that your walkways are clear and well lit.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1742292335\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=see_link\">",
"       Patient information: Dizziness and vertigo (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/59/41905?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15755 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-36135ECCB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41905=[""].join("\n");
var outline_f40_59_41905=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1742292300\">",
"      What are dizziness and vertigo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1742292307\">",
"      What causes vertigo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1742292314\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1742292321\">",
"      How is vertigo treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1742292328\">",
"      What can I do on my own to deal with my vertigo?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1742292335\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/48/35589\">",
"      The vestibular system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/31/41460?source=related_link\">",
"      Patient information: Dizziness and vertigo (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_59_41906="Patient information: Nutrition before and during pregnancy (The Basics)";
var content_f40_59_41906=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/13/7379\">",
"         Patient information: Health and nutrition for women who breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/22/11619\">",
"         Patient information: Preparing for hemodialysis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/15/6387\">",
"         Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/54/31588\">",
"         Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Nutrition before and during pregnancy (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/nutrition-before-and-during-pregnancy-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H2356282\">",
"      <span class=\"h1\">",
"       Will I need to change the way I eat when I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. In fact, you will probably need to change the way you eat",
"      <strong>",
"       before",
"      </strong>",
"      you get pregnant. You will also need to start taking a multivitamin that has",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      in it.",
"     </p>",
"     <p>",
"      If you want to get pregnant, see your doctor or nurse before you start trying. He or she will explain how your diet needs to change and outline the steps you can take to have the healthiest pregnancy possible. &nbsp;",
"     </p>",
"     <p>",
"      Eating the right foods will help your baby&rsquo;s development. Your baby will need nutrients from these foods to form normally and grow.",
"     </p>",
"     <p>",
"      Eating the wrong foods could harm your baby. For example, if you eat cheese made from unpasteurized milk or raw or undercooked meat, you could get an infection that could lead to a miscarriage. Likewise, if you take too much vitamin A (more than 10,000 international units a day) in a vitamin supplement, your baby could be born with birth defects.",
"     </p>",
"     <p>",
"      Making healthy food choices is also important for your health as a mother. As your baby grows and changes inside you, it will take nutrients from your body. You will have to replace these nutrients to stay healthy and have all the energy you need.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356297\">",
"      <span class=\"h1\">",
"       Which foods should I eat?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The best diet for you and your baby will include lots of fresh fruits, vegetables, and whole grains, some low-fat dairy products, and a few sources of protein, such as meat, fish, eggs, or dried peas or beans. If you do not eat dairy foods, you will need to get calcium from other sources. &nbsp;",
"     </p>",
"     <p>",
"      If you are a vegetarian, speak to a nutritionist (food expert) about your food choices. Vegetarian diets can sometimes be missing nutrients that are important for a growing baby. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356312\">",
"      <span class=\"h1\">",
"       Should I prepare food differently?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. You need to be extra careful about avoiding germs in your food. Getting an infection while you are pregnant can cause serious problems.",
"     </p>",
"     <p>",
"      Here's what you should do to avoid germs in your food:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands well with soap and water before you handle food.",
"       </li>",
"       <li>",
"        Make sure to fully cook fish, chicken, beef, eggs, and other meats.",
"       </li>",
"       <li>",
"        Rinse fresh fruits and vegetables under lots of running water before you eat them.",
"       </li>",
"       <li>",
"        When you are done preparing food, wash your hands and anything that touched raw meat or deli meats with hot soapy water. This includes countertops, cutting boards, and knives and spoons.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      To reduce the risk of germs in food, you should also avoid foods that can easily carry germs, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Raw sprouts (including alfalfa, clover, radish, and mung bean)",
"       </li>",
"       <li>",
"        Milk, cheese, or juice that has not been pasteurized (also called unpasteurized)",
"       </li>",
"      </ul>",
"     </p>",
"     <p 1ff8 class=\"headingAnchor\" id=\"H2356327\">",
"      <span class=\"h1\">",
"       Which foods should I avoid?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should avoid certain types of fish and all forms of alcohol. You should also limit the amount of caffeine in your diet, and check with your doctor before taking herbal products.",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        <strong>",
"         Fish",
"        </strong>",
"        &ndash; You should not eat types of fish that could have a lot of mercury in them. These include shark, swordfish, king mackerel, and tilefish. Mercury is a metal that can keep the baby's brain from developing normally.",
"        <br/>",
"        <br/>",
"        You can eat types of fish that do not have a lot of mercury, but not more than 2 times a week. The types of fish and other seafood that are safe to eat 1 or 2 times a week include shrimp, canned light tuna, salmon, pollock, and catfish. Tuna steaks are also OK to eat, but you should have that only 1 time a week.",
"        <br/>",
"        <br/>",
"        Check with your doctor or nurse about the safety of fish caught in local rivers and lakes.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Alcohol",
"        </strong>",
"        &ndash; You should avoid alcohol completely. Even small amounts of alcohol could harm a baby.",
"       </li>",
"       <li>",
"        <strong>",
"         Caffeine",
"        </strong>",
"        &ndash; Limit the amount of caffeine in your diet by not drinking more than 1 or 2 cups of coffee, tea, or cola each day.",
"       </li>",
"       <li>",
"        <strong>",
"         Herbal products",
"        </strong>",
"        &ndash; Check with your doctor or nurse before using herbal products. Some herbal teas may not be safe. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356342\">",
"      <span class=\"h1\">",
"       What are prenatal vitamins?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Prenatal vitamins are vitamin supplements that you take the month before and all through your pregnancy. These vitamins, which also contain minerals (iron, calcium), help make sure that your baby has all the building blocks he or she needs to form healthy organs. Prenatal vitamins help lower the risk of birth defects and other problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356357\">",
"      <span class=\"h1\">",
"       What should I look for in prenatal vitamins?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Choose a multivitamin that&rsquo;s labeled &ldquo;prenatal&rdquo; and that has at least 400 micrograms of",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      . Folic acid is especially important in preventing certain birth defects. Show your doctor or nurse the vitamins you plan to take to make sure the doses are right for you and your baby. Too much of some vitamins can be harmful.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356372\">",
"      <span class=\"h1\">",
"       How much weight should I gain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That will depend on how much you weigh to begin with. Your doctor or nurse will tell you how much weight gain is right for you. In general, a woman who is a healthy weight should gain 25 to 35 pounds during her pregnancy. A woman who is overweight or obese should gain less weight.",
"     </p>",
"     <p>",
"      If you start to lose weight, for example, because you have severe morning sickness, call your doctor or nurse. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356387\">",
"      <span class=\"h1\">",
"       What if I can&rsquo;t afford to eat well?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you can&rsquo;t afford healthy food, ask your doctor or nurse for information about programs that can help you. In the US, there is a government program called &ldquo;WIC&rdquo; that helps women and their families get the nutrition they need. Many states and towns also have local programs to help women who are pregnant or nursing. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H2356402\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/22/11619?source=see_link\">",
"       Patient information: Preparing for hemodialysis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=see_link\">",
"       Patient information: Health and nutrition for women who breastfeed (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/15/6387?source=see_link\">",
"       Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=see_link\">",
"       Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?40/59/41906?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16631 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.28.111.102-85BFFBD9BA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41906=[""].join("\n");
var outline_f40_59_41906=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356282\">",
"      Will I need to change the way I eat when I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356297\">",
"      Which foods should I eat?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356312\">",
"      Should I prepare food differently?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356327\">",
"      Which foods should I avoid?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356342\">",
"      What are prenatal vitamins?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356357\">",
"      What should I look for in prenatal vitamins?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356372\">",
"      How much weight should I gain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356387\">",
"      What if I can&rsquo;t afford to eat well?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2356402\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=related_link\">",
"      Patient informat",
"b61",
"ion: Health and nutrition for women who breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/54/31588?source=related_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/22/11619?source=related_link\">",
"      Patient information: Preparing for hemodialysis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/15/6387?source=related_link\">",
"      Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_59_41907="Anatomy of the stomach";
var content_f40_59_41907=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Anatomy of the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the anatomy of the stomach and the adjacent structures. The short gastric arteries are divided to increase the mobilization of the stomach for exposure of the gastroesophageal junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41907=[""].join("\n");
var outline_f40_59_41907=null;
var title_f40_59_41908="CJD pathology high power";
var content_f40_59_41908=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70414&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High power photomicrograph of classic CJD demonstrating the typical size variation of CJD vacuoles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henry G Brown, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41908=[""].join("\n");
var outline_f40_59_41908=null;
var title_f40_59_41909="Ketorolac (nasal): Patient drug information";
var content_f40_59_41909=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ketorolac (nasal): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/48/4872?source=see_link\">",
"     see \"Ketorolac (nasal): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F12824194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sprix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12841357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is only to be used for 5 days total. It is for very bad, short-term pain. It may cause unsafe side effects if taken more than 5 days. Let your doctor know if you have ulcer disease, kidney disease, a chance of bleeding or any active bleeding, allergies to ketorolac, aspirin, or any other pain drugs. Do not take if you are pregnant or breast-feeding. Tell your doctor if you are 65 years of age or older or weigh less than 110 pounds (50 kilograms).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F12841359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F12841358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ketorolac tromethamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3445773",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to EDTA.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding in the brain, bleeding problems, hole in the GI (gastrointestinal) tract, recent GI bleeding, very bad kidney disease, ulcer disease, or use before surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2980799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 30 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F12841363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696936",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug for more than 5 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 65 or older or weigh less than 110 pound, you may need a smaller dose. You could have more side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F12841364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3445775",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose pain or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F12841366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F12841361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3449024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read and follow how to use facts given with spray. Make sure you use the spray the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3445774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a new spray bottle each day and throw away old spray used the day before.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F12841362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F12841367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699566",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened containers in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3445778",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened nose spray bottle at room temperature. Throw away any unused drug after 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F12841368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16455 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-617C8121F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41909=[""].join("\n");
var outline_f40_59_41909=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12824194\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841357\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841359\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841358\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841363\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841364\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841366\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841361\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841362\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841367\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12841368\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?4/48/4872?source=related_link\">",
"      Ketorolac (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/32/35332?source=related_link\">",
"      Ketorolac (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?19/0/19460?source=related_link\">",
"      Ketorolac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/51/43827?source=related_link\">",
"      Ketorolac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21529?source=related_link\">",
"      Ketorolac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/33/3606?source=related_link\">",
"      Ketorolac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/22/1385?source=related_link\">",
"      Ketorolac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_59_41910="Thymectomy for myasthenia gravis";
var content_f40_59_41910=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Thymectomy for myasthenia gravis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/59/41910/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41910/contributors\">",
"     Shawn J Bird, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/59/41910/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41910/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41910/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41910/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/59/41910/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41910/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41910/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/59/41910/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four basic therapies used to treat myasthenia gravis (MG) (",
"    <a class=\"graphic graphic_table graphicRef70721 \" href=\"mobipreview.htm?4/56/5004\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic treatments (anticholinesterase agents)",
"     </li>",
"     <li>",
"      Chronic immunomodulating treatments (glucocorticoids and other immunosuppressive drugs)",
"     </li>",
"     <li>",
"      Rapid immunomodulating treatments (plasma exchange and intravenous immune globulin)",
"     </li>",
"     <li>",
"      Surgical treatment (thymectomy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will discuss thymectomy for MG. The general approach to the treatment of MG is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link\">",
"     \"Treatment of myasthenia gravis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for thymectomy in patients with myasthenia gravis (MG) relates to the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The thymus may play a role in pathogenesis of myasthenia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link\">",
"       \"Pathogenesis of myasthenia gravis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with MG and autoantibodies directed against the acetylcholine receptor have thymic abnormalities: hyperplasia is found in 60 to 70 percent and thymoma in 10 to 15 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link\">",
"       \"Pathogenesis of myasthenia gravis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=see_link\">",
"       \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, a CT scan or MR imaging of the chest and mediastinum is part of the diagnostic evaluation of all patients with this disorder.",
"   </p>",
"   <p>",
"    Thymectomy is indicated in all patients with thymoma, regardless of the status of MG (eg, generalized, bulbar, ocular). Treatment of a thymoma consists of complete excision or, if this is not possible, radiation for both relief of myasthenic symptoms and prevention of local invasion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Surgical excision for thymoma and thymic carcinoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=see_link\">",
"     \"Clinical presentation and management of thymoma and thymic carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thymectomy in the absence of thymoma is generally considered beneficial for those with generalized MG and acetylcholine receptor (AChR) antibodies, although this has not been established conclusively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. There are numerous other unanswered questions regarding thymectomy. These include the appropriate age for the surgery, when it should be performed in the course of the disease, the surgical approach, and the role of thymectomy in patients with seronegative MG (see",
"    <a class=\"local\" href=\"#H7669757\">",
"     'Seronegative myasthenia'",
"    </a>",
"    below), MuSK antibody-associated MG (see",
"    <a class=\"local\" href=\"#H7669765\">",
"     'MuSK antibody-positive myasthenia'",
"    </a>",
"    below), and purely ocular disease (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/53/7001?source=see_link&amp;anchor=H28#H28\">",
"     \"Ocular myasthenia gravis\", section on 'Thymectomy'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized, controlled trials of the effectiveness of thymectomy for myasthenia gravis (MG) in patients who do not have thymoma, and the benefit and use of thymectomy in the absence of thymoma is still controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/4,8-11\">",
"     4,8-11",
"    </a>",
"    ]. The discussion that follows applies mainly to patients with acetylcholine receptor (AChR) antibody-associated MG.",
"   </p>",
"   <p>",
"    Despite the lack of randomized trials, the available evidence suggests that thymectomy is associated with MG remission and improvement. In a review of the literature published in 2000 by the American Academy of Neurology (AAN) that included 28 observational studies (describing outcomes in patients with and without thymectomy), the following observations were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The association between thymectomy and improved outcomes achieved significance in 7 of 15 studies evaluating medication-free remission, in 8 of 12 studies evaluating asymptomatic patients on or off medication, in 8 of 13 studies evaluating improvement, and in 4 of 13 studies evaluating survival.",
"     </li>",
"     <li>",
"      No study described a significant negative association between thymectomy and any outcome.",
"     </li>",
"     <li>",
"      Based on median relative outcome rates of the observational studies, patients with MG who had thymectomy were two times as likely to attain medication-free remission, 1.6 times as likely to become asymptomatic, and 1.7 times as likely to improve, than patients who did not have thymectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the AAN review noted significant limitations of these studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/4\">",
"     4",
"    </a>",
"    ]. One problem was that different surgical techniques were used, confounding cross-study comparisons. In addition, none of these studies were randomized or used blinded outcome assessments, and in most, thymectomy was performed in younger patients, possibly skewing the data toward a positive outcome for thymectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a later study that analyzed data from 756 patients with MG, thymectomy was significantly associated with MG remission compared with no thymectomy (odds ratio 1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/13\">",
"     13",
"    </a>",
"    ]. Another report of identical twins with MG who were discordant for thymectomy noted that the twin who had thymectomy achieved sustained clinical remission without the use of immunomodulating therapy during 11 years of observation, while the twin who declined thymectomy and immunomodulating therapy remained symptomatic with bilateral ptosis and moderately severe fatigable muscle weakness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even though the likelihood may be 2-fold higher of becoming asymptomatic, or 1.5-fold higher for achieving medication-free remission if thymectomy is performed, the median rate of these outcomes is only 39 and 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/15\">",
"     15",
"    </a>",
"    ]. Others have found somewhat higher rates (40 to 50 percent remission at five years post-thymectomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of thymectomy is not immediate. The one year remission rate is less than 20 percent, but over 7 to 10 years, the remission rate increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/11,15,17\">",
"     11,15,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite these limitations, thymectomy is generally recommended by most centers for patients with generalized AChR antibody-associated MG from puberty to 60 years of age as a long-term therapeutic modality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/5-7,15,19\">",
"     5-7,15,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Surgical approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of thymectomy is to safely remove as much thymic tissue as possible. In addition to the thymus itself, the mediastinal and cervical adipose tissue may contain variable amounts of thymic tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/20\">",
"     20",
"    </a>",
"    ]. The surgical approach should maximize resection of this ectopic thymic tissue while avoiding damage to the recurrent, left vagus, and phrenic nerves.",
"   </p>",
"   <p>",
"    Four operative procedures are used:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transcervical thymectomy",
"     </li>",
"     <li>",
"      Minimally invasive thymectomy (eg, videoscopic, robot-assisted)",
"     </li>",
"     <li>",
"      Transsternal thymectomy",
"     </li>",
"     <li>",
"      Combined transcervical-transsternal thymectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These procedures all remove the thymus, but vary in the extent that the extracapsular mediastinal and cervical fat is resected.",
"   </p>",
"   <p>",
"    There are no convincing data showing superior efficacy or long-term remission rates in MG for any one of these approaches. In the absence of better evidence, there is no consensus as to whether a sternal-splitting approach is better than less invasive techniques, such as extended-transcervical or videoscopic-assisted ones, and the issue awaits an appropriately designed, prospective trial.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sternum-splitting approach (eg, an extended transsternal thymectomy or combined transcervical-transsternal thymectomy) is preferred by many thoracic surgeons and neurologists [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/11,15,16,21,22\">",
"       11,15,16,21,22",
"      </a>",
"      ]. It allows full exploration of the mediastinum into the neck to completely remove all thymic tissue and associated fat.",
"     </li>",
"     <li>",
"      Others advocate an \"extended-cervical thymectomy,\" which minimizes the impact of postoperative pain on ventilatory reserve [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. This requires only brief hospitalization, often one day, and a relatively small scar. This approach uses a special manubrial retractor for improved exposure and resection in the mediastinum, often with the associated use of mediastinoscopy. Some argue that this approach may not adequately expose the entire thymus, thereby increasing the risk of residual thymus being left behind. However, clinical improvement similar to transsternal thymectomy has been reported in several series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/17,24-26\">",
"       17,24-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A simple transcervical procedure does not provide adequate surgical exposure of the thymus, results in significant residual thymus in many patients, and appears to have a lesser outcome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/11,27\">",
"       11,27",
"      </a>",
"      ]. It is rarely performed.",
"     </li>",
"     <li>",
"      Thymectomy using minimally invasive procedures, such as video-assisted thoracoscopy or robot-assisted approaches, has been associated with low morbidity and mortality rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/11,28-33\">",
"       11,28-33",
"      </a>",
"      ]. A retrospective study that compared videoscopic thymectomy with the extended transsternal approach found no significant difference in MG remission rates or favorable outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/32\">",
"       32",
"      </a>",
"      ]. While technically feasible, the effectiveness of minimally invasive procedures compared with \"complete\" transsternal thymectomy awaits confirmation by additional clinical studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with myasthenia are generally at high risk for surgical intervention due to compromised respiratory function, but operative mortality of less than 1 percent can be obtained using current techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there is controversy about which surgical technique is more effective in MG, there is no doubt that the less invasive approaches have a lower morbidity and shorter length of hospitalization than the more invasive ones. As an example, one series of 95 patients with MG found that the mean length of hospital stay was significantly shorter with VATS than with a transsternal approach (1.9 versus 4.6 days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/32\">",
"     32",
"    </a>",
"    ]. In another series of 151 extended transcervical thymectomies, most procedures were performed without the need for overnight hospitalization, and the operative major complication rate was &lt;1 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing for thymectomy in those without thymoma is not established. However, it is probably best to have the patient's MG under reasonable control if possible, with minimal bulbar and respiratory symptoms, to avoid perioperative problems. It is probably also helpful to taper the glucocorticoids as low as the clinical status allows in order to reduce postoperative infections and problems with wound healing.",
"   </p>",
"   <p>",
"    Some have suggested that the response to thymectomy is better if performed early in the disease. This is based on remission rates that are greater if performed early after the onset of disease than if performed later. However, the rate that patients go into remission is higher early in disease. Thus, any intervention performed earlier would appear to do better than if it were performed later in the disease course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]. Despite the lack of a proven benefit of early thymectomy, thymectomy is usually recommended by most experts within the first three years of the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/5,7\">",
"     5,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Patient age and severity of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to thymectomy appears to be roughly comparable in mild, moderate, and severe MG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/4\">",
"     4",
"    </a>",
"    ]. While an age limit for thymectomy has not been established by any of the studies to date for patients without thymoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/4,15\">",
"     4,15",
"    </a>",
"    ], it is thought that older individuals may not have as good a response to thymectomy due to the high incidence of thymic involution, and that the risks of thymectomy may therefore outweigh any potential benefits. Thus, most centers, including our own, do not perform thymectomy for patients age 60 and older. However, others feel that advanced age is not strictly exclusionary and suggest an individualized approach based upon the individual patient&rsquo;s risk and benefit assessment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7669757\">",
"    <span class=\"h2\">",
"     Seronegative myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of thymectomy in patients without thymoma who have seronegative (AChR antibody and MuSK antibody negative) MG has not been established. However, most centers suggest thymectomy as a long term treatment in this cohort under the same conditions (age, clinical status, etc.) as with those who are AChR-antibody positive. A retrospective cohort study of these two groups (AChR antibody positive and negative) found a similar response rate with a minimum three year follow-up period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7669765\">",
"    <span class=\"h2\">",
"     MuSK antibody-positive myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of rare patients with thymoma, patients with MuSK-antibody associated MG have a much lower frequency of thymic pathology than patients with AChR-antibody associated MG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link&amp;anchor=H8#H8\">",
"     \"Diagnosis of myasthenia gravis\", section on 'MuSK antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available evidence does not support a role for thymectomy in MuSK antibody-associated MG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/5\">",
"     5",
"    </a>",
"    ]. In one series of 110 patients with MuSK-positive MG, 40 patients who underwent thymectomy had a post-intervention status comparable to 70 patients who did not undergo surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/36\">",
"     36",
"    </a>",
"    ]. This observation does not exclude the possibility that thymectomy may be beneficial, but many centers, including our own, do not recommend thymectomy in patients without thymoma who have MuSK-positive MG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ocular myasthenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of thymectomy in ocular MG is controversial. While it may be as beneficial as in those with generalized disease, some centers do not advise thymectomy for patients with ocular MG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/15\">",
"     15",
"    </a>",
"    ]. Other centers, particularly those where the less invasive extended transsternal procedure is performed (like ours), offer this as a therapeutic option.",
"   </p>",
"   <p>",
"    Thymectomy for ocular myasthenia gravis is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/53/7001?source=see_link&amp;anchor=H28#H28\">",
"     \"Ocular myasthenia gravis\", section on 'Thymectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is sometimes a transient postoperative increase in myasthenic symptoms. Several factors that are associated with postoperative myasthenic crisis, or the need for prolonged mechanical ventilation, have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41910/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperative expiratory weakness",
"     </li>",
"     <li>",
"      Preoperative vital capacity of less than 2.0 L",
"     </li>",
"     <li>",
"      Preoperative bulbar symptoms",
"     </li>",
"     <li>",
"      History of preoperative myasthenic crisis",
"     </li>",
"     <li>",
"      Preoperative acetylcholine receptor antibody serum level of greater than 100",
"      <span class=\"nowrap\">",
"       nmol/L",
"      </span>",
"     </li>",
"     <li>",
"      Intraoperative blood loss greater than 1000 mL",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Extra vigilance is warranted in the postoperative periods for patients with these poor prognostic factors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6311?source=see_link\">",
"     \"Myasthenic crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with preoperative respiratory or bulbar symptoms, treatment with one of the rapid immunotherapies - plasmapheresis or intravenous immune globulin - is warranted prior to surgery. This is usually sufficient to get the patient through the postoperative period. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of myasthenia gravis\", section on 'Rapid immunotherapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a general rule, the indications, timing, and pre and postoperative care of a patient with MG undergoing thymectomy should be managed by the surgeon in close collaboration with a neurologist or other practitioner with expertise in MG.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are four basic therapies used to treat myasthenia gravis (MG): symptomatic treatments (anticholinesterase agents), chronic immunotherapies (glucocorticoids and other immunosuppressive drugs), rapid immunotherapies (plasma exchange and intravenous immune globulin), and surgical treatment (thymectomy) (",
"      <a class=\"graphic graphic_table graphicRef70721 \" href=\"mobipreview.htm?4/56/5004\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rationale for thymectomy in patients with acetylcholine receptor antibody-positive MG relates to observations that the thymus may play a role in pathogenesis of MG, and that most patients with MG have thymic abnormalities. Thymectomy is indicated in all patients with thymoma, regardless of the status of MG (eg, generalized, bulbar, ocular, etc). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thymectomy for MG in patients who do not have thymoma appears to be associated with about a twofold likelihood of becoming asymptomatic or achieving medication-free remission, although there are no data from randomized trials. However, the benefit of thymectomy is not immediate, and thymectomy is not beneficial for everyone: the median rate of becoming asymptomatic is about 40 percent, and the median rate of achieving medication-free remission is about 25 to 50 percent at five years post-thymectomy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several different surgical approaches are available in the absence of obvious thymoma. The goal of thymectomy is to safely remove as much thymic tissue as possible. This includes the thymus itself, as well as any potential extracapsular thymic tissue in the anterior mediastinal adipose tissue. There is no consensus as to whether a sternal-splitting approach is better than less invasive techniques, such as an extended-transcervical or videoscopic-assisted approaches. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Surgical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal timing of thymectomy for MG is not established. However, it is probably best to have the MG under reasonable control if possible, with minimal bulbar and respiratory symptoms, to avoid perioperative problems. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Timing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Thymectomy is generally suggested for patients who are seronegative for both AChR and MuSK antibodies (ie, seronegative MG). However, the available evidence does not support a role for thymectomy in patients without thymoma who have MuSK-positive MG. (See",
"      <a class=\"local\" href=\"#H7669757\">",
"       'Seronegative myasthenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7669765\">",
"       'MuSK antibody-positive myasthenia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The role of thymectomy in ocular MG is controversial. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/53/7001?source=see_link&amp;anchor=H28#H28\">",
"       \"Ocular myasthenia gravis\", section on 'Thymectomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest thymectomy for patients without thymoma below age 60 years who have generalized MG and either have AChR antibodies, or have no detectable AChR or MuSK antibodies (ie, seronegative MG) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest",
"      <strong>",
"       not",
"      </strong>",
"      performing thymectomy in patients with MuSK antibody-associated MG without thymoma (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Patient age and severity of disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link&amp;anchor=H21#H21\">",
"       \"Treatment of myasthenia gravis\", section on 'Age 60 and over'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest treatment with one of the rapid immunotherapies - plasmapheresis or intravenous immune globulin - for patients with preoperative respiratory or bulbar symptoms prior to any surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The perioperative care of a patient with MG undergoing thymectomy should be managed by the surgeon in close collaboration with a neurologist or practitioner with expertise in MG (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Perioperative considerations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of myasthenia gravis\", section on 'Rapid immunotherapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/1\">",
"      Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/2\">",
"      Giaccone G. Treatment of malignant thymoma. Curr Opin Oncol 2005; 17:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/3\">",
"      Romi F. Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis 2011; 2011:474512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/4\">",
"      Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/5\">",
"      Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/6\">",
"      Jani-Acsadi A, Lisak RP. Myasthenia gravis. Curr Treat Options Neurol 2010; 12:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/7\">",
"      Kumar V, Kaminski HJ. Treatment of myasthenia gravis. Curr Neurol Neurosci Rep 2011; 11:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/8\">",
"      Buckingham JM, Howard FM Jr, Bernatz PE, et al. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg 1976; 184:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/9\">",
"      Nieto IP, Robledo JP, Pajuelo MC, et al. Prognostic factors for myasthenia gravis treated by thymectomy: review of 61 cases. Ann Thorac Surg 1999; 67:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/10\">",
"      Roberts PF, Venuta F, Rendina E, et al. Thymectomy in the treatment of ocular myasthenia gravis. J Thorac Cardiovasc Surg 2001; 122:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/11\">",
"      Jaretzki A, Steinglass KM, Sonett JR. Thymectomy in the management of myasthenia gravis. Semin Neurol 2004; 24:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/12\">",
"      Kissel JT, Franklin GM. Treatment of myasthenia gravis: A call to arms. Neurology 2000; 55:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/13\">",
"      Mantegazza R, Baggi F, Antozzi C, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 2003; 998:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/14\">",
"      Riggs KR, Gutmann L, Riggs JE. Discordant thymectomy in identical twins concordant for myasthenia gravis. Ann Intern Med 2011; 155:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/15\">",
"      Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol 2004; 24:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/16\">",
"      Jaretzki A 3rd, Aarli JA, Kaminski HJ, et al. Thymectomy for myasthenia gravis: evaluation requires controlled prospective studies. Ann Thorac Surg 2003; 76:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/17\">",
"      Shrager JB, Deeb ME, Mick R, et al. Transcervical thymectomy for myasthenia gravis achieves results comparable to thymectomy by sternotomy. Ann Thorac Surg 2002; 74:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/18\">",
"      Mantegazza R, Baggi F, Bernasconi P, et al. Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. J Neurol Sci 2003; 212:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/19\">",
"      Richman DP, Agius MA. Treatment of autoimmune myasthenia gravis. Neurology 2003; 61:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/20\">",
"      Sonett JR, Jaretzki A 3rd. Thymectomy for nonthymomatous myasthenia gravis: a critical analysis. Ann N Y Acad Sci 2008; 1132:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/21\">",
"      Jaretzki A 3rd, Wolff M. \"Maximal\" thymectomy for myasthenia gravis. Surgical anatomy and operative technique. J Thorac Cardiovasc Surg 1988; 96:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/22\">",
"      Masaoka A. Extended trans-sternal thymectomy for myasthenia gravis. Chest Surg Clin N Am 2001; 11:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/23\">",
"      Papatestas AE, Genkins G, Kornfeld P, et al. Transcervical thymectomy in myasthenia gravis. Surg Gynecol Obstet 1975; 140:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/24\">",
"      Bril V, Kojic J, Ilse WK, Cooper JD. Long-term clinical outcome after transcervical thymectomy for myasthenia gravis. Ann Thorac Surg 1998; 65:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/25\">",
"      Calhoun RF, Ritter JH, Guthrie TJ, et al. Results of transcervical thymectomy for myasthenia gravis in 100 consecutive patients. Ann Surg 1999; 230:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/26\">",
"      Meyers BF, Cooper JD. Transcervical thymectomy for myasthenia gravis. Chest Surg Clin N Am 2001; 11:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/27\">",
"      Zieli��ski M, Kuzdzal J, Szlubowski A, Soja J. Comparison of late results of basic transsternal and extended transsternal thymectomies in the treatment of myasthenia gravis. Ann Thorac Surg 2004; 78:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/28\">",
"      Bachmann K, Burkhardt D, Schreiter I, et al. Long-term outcome and quality of life after open and thoracoscopic thymectomy for myasthenia gravis: analysis of 131 patients. Surg Endosc 2008; 22:2470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/29\">",
"      Meacci E, Cesario A, Margaritora S, et al. Thymectomy in myasthenia gravis via original video-assisted infra-mammary cosmetic incision and median sternotomy: long-term results in 180 patients. Eur J Cardiothorac Surg 2009; 35:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/30\">",
"      Pompeo E, Tacconi F, Massa R, et al. Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis. Eur J Cardiothorac Surg 2009; 36:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/31\">",
"      Tomulescu V, Sgarbura O, Stanescu C, et al. Ten-year results of thoracoscopic unilateral extended thymectomy performed in nonthymomatous myasthenia gravis. Ann Surg 2011; 254:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/32\">",
"      Meyer DM, Herbert MA, Sobhani NC, et al. Comparative clinical outcomes of thymectomy for myasthenia gravis performed by extended transsternal and minimally invasive approaches. Ann Thorac Surg 2009; 87:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/33\">",
"      Marulli G, Rea F, Melfi F, et al. Robot-aided thoracoscopic thymectomy for early-stage thymoma: a multicenter European study. J Thorac Cardiovasc Surg 2012; 144:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/34\">",
"      Khicha SG, Kaiser LR, Shrager JB. Extended transcervical thymectomy in the treatment of myasthenia gravis. Ann N Y Acad Sci 2008; 1132:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/35\">",
"      Guillermo GR, T&eacute;llez-Zenteno JF, Weder-Cisneros N, et al. Response of thymectomy: clinical and pathological characteristics among seronegative and seropositive myasthenia gravis patients. Acta Neurol Scand 2004; 109:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/36\">",
"      Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/37\">",
"      Loach AB, Young AC, Spalding JM, Smith AC. Postoperative management after thymectomy. Br Med J 1975; 1:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/38\">",
"      Gracey DR, Divertie MB, Howard FM Jr, Payne WS. Postoperative respiratory care after transsternal thymectomy in myasthenia gravis. A 3-year experience in 53 patients. Chest 1984; 86:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/39\">",
"      Younger DS, Braun NM, Jaretzki A 3rd, et al. Myasthenia gravis: determinants for independent ventilation after transsternal thymectomy. Neurology 1984; 34:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41910/abstract/40\">",
"      Watanabe A, Watanabe T, Obama T, et al. Prognostic factors for myasthenic crisis after transsternal thymectomy in patients with myasthenia gravis. J Thorac Cardiovasc Surg 2004; 127:868.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5127 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-2.133.93.82-3DA446CC7F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41910=[""].join("\n");
var outline_f40_59_41910=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Surgical approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Patient age and severity of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7669757\">",
"      Seronegative myasthenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7669765\">",
"      MuSK antibody-positive myasthenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ocular myasthenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PERIOPERATIVE CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5127\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5127|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/56/5004\" title=\"table 1\">",
"      Therapies for MG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/17/8474?source=related_link\">",
"      Clinical presentation and management of thymoma and thymic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6311?source=related_link\">",
"      Myasthenic crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/53/7001?source=related_link\">",
"      Ocular myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=related_link\">",
"      Pathogenesis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_59_41911="Hemi-uterus1";
var content_f40_59_41911=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67507%7EOBGYN%2F81269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67507%7EOBGYN%2F81269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Laparoscopic view of left hemiuterus communicating with single cervix as demonstrated by flow of blue dye injected through the cervix \"freely spilling\" from left fallopian tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right hemiuterus does not communicate with the cervix and should be removed laparoscopically.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from:&nbsp;Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Noncommunicating right hemiuterus has been removed laparoscopically; left functional unicornuate system is intact",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Laufer MR. Structural abnormalities of the female reproductive tract. In: Pediatric and adolescent gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41911=[""].join("\n");
var outline_f40_59_41911=null;
var title_f40_59_41912="Hypovolemic shock in children: Initial evaluation and management";
var content_f40_59_41912=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypovolemic shock in children: Initial evaluation and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/59/41912/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41912/contributors\">",
"     Wendy J Pomerantz, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41912/contributors\">",
"     Mark G Roback, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/59/41912/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41912/contributors\">",
"     Susan B Torrey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41912/contributors\">",
"     Adrienne G Randolph, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/59/41912/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/59/41912/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/59/41912/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemic shock is characterized by inadequate tissue perfusion from decreased intravascular volume as the result of fluid loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequate fluid intake. The challenge for the clinician is to recognize children in hypovolemic shock early (before they develop hypotension), when they are more likely to respond favorably to treatment. Effective initial management of hypovolemic shock requires aggressive fluid resuscitation and control of ongoing losses (as with hemorrhage). Subsequent treatment includes repletion of deficits (based upon the type and amount of fluid that has been lost) and correction of metabolic abnormalities (ie, hypoglycemia and electrolyte disturbances).",
"   </p>",
"   <p>",
"    This topic will review the evaluation and treatment of hypovolemic shock in children. A general approach to the initial evaluation and management of shock in children, evaluation and treatment of hypovolemia in children, and the pathophysiology of shock are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link\">",
"       \"Initial evaluation of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link\">",
"       \"Initial management of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link\">",
"       \"Treatment of hypovolemia (dehydration) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42901?source=see_link\">",
"       \"Physiology and classification of shock in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sources of volume loss that can lead to hypovolemic shock include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vomiting",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea",
"     </li>",
"     <li>",
"      Osmotic diuresis (eg, hyperglycemia)",
"     </li>",
"     <li>",
"      Capillary leak (eg, sepsis, intraabdominal processes with third space losses [eg, pancreatitis, intussusception, appendicitis], or burn injury)",
"     </li>",
"     <li>",
"      Hemorrhage",
"     </li>",
"     <li>",
"      Inadequate fluid intake (particularly among infants and young children who cannot independently access fluids to replenish losses)",
"     </li>",
"     <li>",
"      Insensible losses (eg, fever or burns)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Worldwide, hypovolemic shock from diarrheal disease is a major cause of death among children younger than five years of age living in resource poor countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemorrhagic shock in children is most often the result of major trauma. Less common causes include gastrointestinal bleeding, postoperative bleeding, and pulmonary hemorrhage. Sickle cell anemia complicated by sequestration crisis can result in physiologic complications similar to hemorrhagic shock. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=see_link\">",
"     \"Overview of blunt abdominal trauma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypovolemic shock develops when intravascular volume is insufficient to maintain tissue perfusion. Fluid losses may be strictly intravascular (eg, hemorrhage, third-space losses from intraabdominal processes [eg, pancreatitis, intussusception, appendicitis] or capillary leak), a combination of intravascular and extravascular (eg, burn injury), or primarily extravascular (eg, diarrheal disease). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Type of fluid lost'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial compensation for volume depletion includes stimulation of thirst and fluid conservation by the kidneys. The following mechanisms come into play once perfusion becomes compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachycardia increases cardiac output. However shortened ventricular filling time can result in decreased stroke volume and worsening cardiac output.",
"     </li>",
"     <li>",
"      Increased systemic vascular resistance (SVR), mediated by the sympathetic nervous and renin-angiotensin systems, results in redistribution of blood flow from peripheral structures (including skin, muscle, kidneys, and splanchnic organs) to the heart and central nervous system.",
"     </li>",
"     <li>",
"      Increased cardiac contractility can maintain stroke volume by increasing ventricular emptying.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among children with hypovolemic shock, hypotension develops late, typically when intravascular volume is decreased by 30 percent or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/3\">",
"     3",
"    </a>",
"    ]. Compensatory vasoconstriction maintains blood pressure at the expense of reduced tissue perfusion. As a result, hypovolemic shock progresses rapidly to cardiovascular collapse and cardiac arrest once hypotension develops. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42901?source=see_link\">",
"     \"Physiology and classification of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypovolemia can be classified by the degree of volume depletion, with patients in shock included in the most severe categories.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with nonhemorrhagic losses, volume depletion is characterized as mild, moderate, or severe depending upon the percent loss of body weight: 3 to 5 percent (mild), 6 to 9 percent (moderate), and 10 percent or more (severe). Clinical features are typically used to estimate volume deficit since premorbid weight is usually not known (",
"      <a class=\"graphic graphic_table graphicRef76198 \" href=\"mobipreview.htm?13/5/13404\">",
"       table 1",
"      </a>",
"      ). Many children with moderate volume depletion and all of those with severe depletion have compromised perfusion and are in shock. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Degree of dehydration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with hemorrhage can be categorized by severity into four classes based upon percent loss of blood volume. As with nonhemorrhagic losses, clinical features are typically used to estimate blood volume deficit (",
"      <a class=\"graphic graphic_table graphicRef68694 \" href=\"mobipreview.htm?33/47/34556\">",
"       table 2",
"      </a>",
"      ). Many children with class II hemorrhage and all of those with classes III and IV are in shock. The approach to hemorrhage by class is as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Class I",
"      </strong>",
"      &ndash; Class I hemorrhage occurs with acute loss of up to 15 percent of the child's blood volume. Minimal physiologic changes are evident and patients usually respond well to crystalloid fluid replacement.",
"     </li>",
"     <li>",
"      <strong>",
"       Class II",
"      </strong>",
"      &ndash; Class II hemorrhage results from 15 to 30 percent blood loss. Physiologic changes include mild tachycardia and tachypnea with a narrow pulse pressure, slightly delayed capillary refill, decreased urine output, and mild anxiety. Patients can usually be stabilized with crystalloid solution, although they may require blood products.",
"     </li>",
"     <li>",
"      <strong>",
"       Class III",
"      </strong>",
"      &ndash; Class III hemorrhage is the result of an acute blood loss of 30 to 40 percent. Signs of shock (including tachycardia, tachypnea, hypotension, delayed capillary refill, altered mental status, and oliguria) are present. Prompt resuscitation with crystalloid solution is necessary; most patients will need blood products as well.",
"     </li>",
"     <li>",
"      <strong>",
"       Class IV",
"      </strong>",
"      &ndash; Class IV hemorrhage occurs with more than 40 percent acute blood loss. Signs of shock are obvious and immediately life-threatening. Patients are usually cold and pale with profoundly depressed mentation, marked tachypnea and tachycardia, and anuria. Children should quickly receive blood products. Operative intervention is often necessary to control hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical characteristics associated with imminent cardiovascular collapse must be quickly identified with an initial rapid assessment. Children who have been injured and have hemorrhagic hypovolemic shock may have associated injuries that require stabilization (ie, cervical spine immobilization for suspected neck injury or needle thoracostomy for tension pneumothorax). An approach to rapidly identifying the cause of shock based upon clinical findings is provided in the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"mobipreview.htm?1/61/2000\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial evaluation of shock in children\", section on 'Rapid assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical features typically suggest the source of volume loss (ie, vomiting and diarrhea with gastroenteritis, osmotic diuresis with diabetic ketoacidosis, insensible and capillary leak following burn injury, third space losses with intraabdominal processes [eg, pancreatitis, intussusception, small bowel obstruction], sickle cell disease with splenic sequestration crisis, or hemorrhage with blunt abdominal trauma).",
"   </p>",
"   <p>",
"    Additional key historical information to consider includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The type of fluid loss may influence fluid management (ie, blood transfusion for children with hemorrhage or isotonic fluids followed by slower administration of hypotonic fluids in patients with hypernatremic dehydration). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link&amp;anchor=H94208716#H94208716\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Hypernatremia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior fluid replacement may cause abnormalities in serum electrolyte levels (ie, hyponatremia from fluid replacement with free water, typically in young infants). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link&amp;anchor=H94208684#H94208684\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Hyponatremia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings for children with hypovolemic shock are similar to those of patients with shock from other causes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial evaluation of shock in children\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of decreased cerebral perfusion (ie, poor tone, unfocused gaze, listlessness, or decreased responsiveness to caretakers or painful interventions)",
"     </li>",
"     <li>",
"      Signs of poor peripheral perfusion (ie, decreased or absent distal pulses, cool extremities, prolonged capillary refill [&gt;2 seconds])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific features of the physical examination that may be noted in children with hypovolemic shock include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who are hypotensive with histories of trauma are likely in hemorrhagic shock. They must be carefully evaluated to identify sources of bleeding and associated injuries (",
"      <a class=\"graphic graphic_figure graphicRef64241 \" href=\"mobipreview.htm?42/51/43834\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"       \"Trauma management: Approach to the unstable child\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with hypovolemic shock typically have narrow pulse pressures as the result of elevated diastolic pressure from increased systemic vascular resistance.",
"     </li>",
"     <li>",
"      Signs of significant volume loss may be less dramatic among children with hypertonic dehydration (as can occur with hypotonic fluid loss from conditions such as rotavirus gastroenteritis and diabetes insipidus). This is because the associated increase in serum osmolality pulls water out of the cells, initially minimizing the degree of extracellular fluid volume loss. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Type of fluid lost'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal distention, mass, or tenderness is consistent with an abdominal catastrophe, such as bowel obstruction, perforation, or peritonitis. Inflicted injury should be considered in the absence of a history of trauma. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19497?source=see_link&amp;anchor=H11#H11\">",
"       \"Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis\", section on 'Abdominal injuries'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ongoing losses must be identified (ie, persistent vomiting, diarrhea, or active bleeding). They may need to be replaced",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treated.",
"     </li>",
"     <li>",
"      Children with moderate to severe burns are at increased risk of hypovolemia due to insensible losses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44201?source=see_link&amp;anchor=H18#H18\">",
"       \"Emergency care of moderate and severe thermal burns in children\", section on 'Evaluation of burn injury'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ancillary data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hypovolemic shock usually is based upon physical signs and symptoms. Once fluid therapy is initiated, ancillary data can be useful to detect associated electrolyte and acid-base abnormalities and to guide treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Laboratory evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hypovolemic shock without hemorrhage",
"      </strong>",
"      &ndash; The following studies are suggested in children with hypovolemic shock without hemorrhage:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Rapid blood glucose",
"      </strong>",
"      &ndash; Children with hypovolemic shock from gastroenteritis are at risk for hypoglycemia. In contrast, pediatric trauma and burn victims commonly have hyperglycemia caused by physiologic stress. In some of these patients, the blood glucose can exceed 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (16.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      with the potential to cause an osmotic diuresis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Electrolyte levels",
"      </strong>",
"      &ndash; Abnormalities in serum sodium and potassium levels may occur among children with hypovolemic shock. Serum sodium concentrations are influenced by the type of fluid loss, secretion of antidiuretic hormone, and prior fluid replacement. Clinical features that affect serum potassium include type of fluid loss (ie, increased loss in diarrheal stool) and the degree of acidosis (with marked acidosis, serum potassium concentration may be increased). Serum and urine electrolyte testing in hypovolemia is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=see_link&amp;anchor=H6#H6\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Laboratory testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Urine dipstick",
"      </strong>",
"      &ndash; Rapid urine dipstick provides a quick measurement of the urine specific gravity, ketones, and glucose. Glycosuria with ketones suggests diabetic ketoacidosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Hemorrhagic hypovolemic shock",
"      </strong>",
"      &ndash; In addition to the studies suggested above, children with hemorrhagic hypovolemic shock warrant the following studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Hematocrit",
"      </strong>",
"      &ndash; Most children with hemorrhagic shock have acute blood loss. The initial hematocrit is typically normal because equilibration with extracellular fluid has not yet occurred. However, the hematocrit will drop with repeated measurements over time. Patients with hemorrhagic shock and a low initial hematocrit often have life-threatening hemorrhage.",
"      <br/>",
"      <br/>",
"      In patients with hypovolemic shock primarily from fluid losses such as diarrhea, the hematocrit may be elevated due to hemoconcentration.",
"     </li>",
"     <li>",
"      <strong>",
"       Coagulation studies (platelet count, PT, aPTT, INR, fibrinogen) &ndash;",
"      </strong>",
"      In patients with ongoing hemorrhage and known or suspected thrombocytopenia (eg, post-chemotherapy, bone marrow transplant, ITP, etc), liver dysfunction, anticoagulant therapy, massive transfusion (volume of blood received equivalent to total blood volume), or with significant bleeding to the extent that their clotting ability has been diminished, the hemorrhage may not stop until coagulation parameters are corrected. Evaluation of platelet count, PT, and PTT can assist in identifying coagulopathy and guiding correction with platelet infusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fresh frozen plasma. Fibrinogen should also be checked in patients with liver dysfunction as cryoprecipitate may be needed to more effectively replace liver-dependent clotting factors (factors II, VII, IX, and X).",
"     </li>",
"     <li>",
"      <strong>",
"       Type and cross match",
"      </strong>",
"      &ndash; Children with hemorrhagic shock may require urgent transfusion. Although typed and cross-matched blood products are preferred, they may take 30 to 45 minutes to prepare. Type-specific blood can usually be obtained within 15 to 20 minutes. Type O Rh-positive for males and type O Rh-negative for females can be used for patients who require immediate transfusion. Hypocalcemia and coagulation abnormalities may develop in patients who require massive transfusion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H27380186#H27380186\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Blood products'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=see_link\">",
"       \"Massive blood transfusion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Blood gas measurements",
"      </strong>",
"      &ndash; Patients with hypovolemic shock develop lactic acidosis caused by inadequate tissue oxygenation and perfusion. Thus, metabolic acidosis is typically present on arterial or venous blood gases. Metabolic acidosis can also be evident by lowered carbon dioxide measurements obtained by capnography. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=see_link&amp;anchor=H17#H17\">",
"       \"Carbon dioxide monitoring (capnography)\", section on 'Detecting metabolic acidosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A chest radiograph can be useful to evaluate heart size for children with apparent hypovolemic shock who do not improve following the administration of 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of fluid. If the heart size is small, then additional bolus fluid administration is indicated. In contrast, if the heart is big, then fluid therapy should be moderated and additional types of shock (eg, septic or cardiogenic shock) may be present and warrant specific therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4634?source=see_link\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link&amp;anchor=H13#H13\">",
"     \"Initial management of shock in children\", section on 'Specific management decisions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with traumatic hemorrhagic shock, a chest radiograph may identify intrathoracic bleeding or other causes for shock, such as tension pneumothorax or pericardial effusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H23#H23\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Screening radiographs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children with trauma, additional imaging is typically warranted. The approach to imaging in the pediatric trauma patient is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H21#H21\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Adjuncts to the primary survey'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H37#H37\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Adjuncts to the secondary survey'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful management of children with hypovolemic shock requires identification and treatment of life-threatening conditions and the rapid initiation of aggressive fluid resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial evaluation of shock in children\", section on 'Rapid assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564128\">",
"    <span class=\"h2\">",
"     Airway and breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For hemorrhagic hypovolemic shock due to blunt trauma, patients should have a rigid cervical collar in place and full spinal immobilization until a spinal fracture can be ruled out. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H10#H10\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Airway'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6854?source=see_link\">",
"     \"Pediatric cervical spine immobilization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link\">",
"     \"Evaluation of cervical spine injuries in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Airway management should include supplemental oxygen with an initial inspired concentration of 100 percent. Early positive pressure ventilation and intubation should be performed in patients with airway compromise or impending respiratory failure. A rapid overview provides the suggested approach to rapid sequence intubation in children (",
"    <a class=\"graphic graphic_table graphicRef51456 \" href=\"mobipreview.htm?17/26/17837\">",
"     table 3",
"    </a>",
"    ). Children with hemodynamic instability from hypovolemic shock should receive sedation using either",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"     etomidate",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/18/40229?source=see_link\">",
"     ketamine",
"    </a>",
"    prior to intubation. The clinician should",
"    <strong>",
"     avoid",
"    </strong>",
"    the routine use of etomidate in children who also have presumed (suspicion for) septic shock. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial management of shock in children\", section on 'Airway management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"     \"Rapid sequence intubation (RSI) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Control of hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sites of significant external hemorrhage require direct manual pressure to control bleeding (",
"    <a class=\"graphic graphic_figure graphicRef75556 \" href=\"mobipreview.htm?35/14/36078\">",
"     figure 2",
"    </a>",
"    ). The presence of nerves near vascular bundles prohibits blind clamping of bleeding vessels except in the scalp. In patients whose bleeding does not abate with direct pressure or who have a sharp foreign body at the site of bleeding or an amputation, compression at the nearest vascular pressure point provides an alternative means for hemorrhage control (",
"    <a class=\"graphic graphic_figure graphicRef75765 \" href=\"mobipreview.htm?28/16/28937\">",
"     figure 3",
"    </a>",
"    ). Finally, the medical provider may employ a blood pressure tourniquet or Penrose drain tourniquet for severe bleeding that is poorly controlled despite direct pressure or compression of pressure points. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H13#H13\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Hemorrhage control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe bleeding from a large scalp laceration often responds to rapid closure using a figure of eight suture, surgical staples, or scalp clips (Raney clips). A circumferential Penrose drain tourniquet can provide temporary control of scalp bleeding until repair is complete (",
"    <a class=\"graphic graphic_figure graphicRef73415 \" href=\"mobipreview.htm?7/23/7538\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33124?source=see_link\">",
"     \"Closure of minor skin wounds with staples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reduction and splinting of long bone fractures may also provide hemostasis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with a suspected pelvic fracture and hemodynamic instability, clinicians should carefully examine the perineum and rectum and then place a pelvic stabilization device over the greater trochanter (prefabricated pelvic binder or a bed sheet tied tightly around the pelvis) (",
"    <a class=\"graphic graphic_figure graphicRef76777 \" href=\"mobipreview.htm?9/7/9331\">",
"     figure 5",
"    </a>",
"    ). External fixation devices are generally placed in the operating room because placement can be difficult and time consuming and may interfere with other components of resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H13#H13\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Hemorrhage control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with pulmonary hemorrhage from a diffuse lung process, endotracheal intubation and mechanical ventilation with increased positive end-expiratory pressure may help to &ldquo;tamponade&rdquo; or slow the bleeding and permit oxygenation. The diagnostic approach and management of severe hemoptysis in children is discussed in detail separately.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37896?source=see_link&amp;anchor=H9#H9\">",
"     \"Hemoptysis in children\", section on 'Diagnostic approach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37896?source=see_link&amp;anchor=H16#H16\">",
"     \"Hemoptysis in children\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vascular access",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate vascular access must be obtained for rapid infusion of fluid. Two peripheral intravenous catheters consisting of the largest bore, shortest length, that can be reliably placed (22 to 24 gauge in newborns and infants, 18 to 20 gauge for older children) typically suffice. Ideally, at least one of the two access sites should be above the diaphragm (upper extremity, external jugular vein, or scalp vein) in the event that the patient has diminished inferior vena cava blood return due to traumatic disruption or extrinsic compression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8057?source=see_link&amp;anchor=H5#H5\">",
"     \"Vascular (venous) access for pediatric resuscitation and other pediatric emergencies\", section on 'Catheter selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children in shock, intraosseous cannulation should be performed if IV access cannot be established quickly. During CPR or the treatment of severe shock, intraosseous cannulation, and peripheral venous access should be pursued simultaneously [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40761?source=see_link&amp;anchor=H3#H3\">",
"     \"Intraosseous infusion\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Fluid resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of fluid therapy is rapid restoration of intravascular volume. Children with hypovolemic shock should receive isotonic crystalloid, such as normal saline or lactated Ringer&rsquo;s solution. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link&amp;anchor=H6#H6\">",
"     \"Initial management of shock in children\", section on 'Crystalloid versus colloid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limited evidence exists concerning the optimal amount and rate of fluid administration for children with hypovolemic shock although aggressive fluid resuscitation is associated with improved outcomes in children with uncompensated septic shock. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial management of shock in children\", section on 'Fluid administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of hypovolemic shock determines the volume and rate of initial fluid administration (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link&amp;anchor=H5#H5\">",
"     \"Initial management of shock in children\", section on 'Fluid administration'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with decompensated hypovolemic shock should receive 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per bolus of isotonic crystalloid, such as normal saline or Ringer's lactate solution, infused over 5 to 10 minutes and repeated, as needed, up to",
"      <strong>",
"       three",
"      </strong>",
"      times in patients without improvement and",
"      <strong>",
"       no",
"      </strong>",
"      signs of fluid overload. Additional therapies, such as blood transfusion in patients with hypovolemic shock from hemorrhage may be required depending upon the response to fluid administration.",
"      <br/>",
"      <br/>",
"      Techniques to rapidly deliver intravenous fluid include applying pressure directly to the bag of fluid with an inflatable device, delivering aliquots of fluid using a large syringe that is refilled through a three-way stopcock attached to the bag (the \"push-pull\" method) or use of rapid infusion pumps designed to deliver high volumes of warmed fluids or blood. Gravity alone is unlikely to deliver 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      over 5 to 10 minutes.",
"     </li>",
"     <li>",
"      Children with compensated hypovolemic shock may receive 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per bolus of isotonic crystalloid, such as normal saline or Ringer's lactate solution over 5 to 20 minutes. Patients should be closely monitored during fluid administration. Additional fluid boluses may be indicated depending upon the patients&rsquo; response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the initial fluid bolus, the following physiologic indicators of perfusion (with therapeutic goals in parentheses) should be evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Quality of central and peripheral pulses (strong, distal pulses equal to central pulses)",
"     </li>",
"     <li>",
"      Skin perfusion (warm, with capillary refill &lt;2 seconds)",
"     </li>",
"     <li>",
"      Mental status (normal mental status)",
"     </li>",
"     <li>",
"      Urine output (&ge;1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour, once effective circulating volume is restored)",
"     </li>",
"     <li>",
"      Blood pressure (systolic pressure at least fifth percentile for age: 60 mmHg &lt;1 month of age, 70 mmHg + [2 x age in years] in children 1 month to 10 years of age, 90 mmHg in children 10 years of age or older)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormalities in blood glucose, electrolyte, and calcium measurements should be identified and treatment initiated. Children who have not improved should continue to receive isotonic crystalloid in 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    boluses to a total of 60",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    ideally within the first 30 to 60 minutes of treatment. Patients with hemorrhagic shock typically require 3 mL of crystalloid to replace each milliliter of blood lost [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should be examined for physiologic indicators of peripheral perfusion and signs of fluid overload (decreased oxygenation, crackles, gallop rhythm, hepatomegaly) before and after each bolus.",
"   </p>",
"   <p>",
"    In most children with hypovolemic shock, rapid improvement occurs with initial fluid administration. Children who have not improved after receiving a total of 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic fluid should be evaluated for other causes of shock. Patients with apparent nonhemorrhagic hypovolemic shock may have associated conditions (eg, septic shock, heart failure from myocarditis). Children with traumatic hemorrhagic shock may have additional injuries (ie, spinal cord injury). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=see_link\">",
"     \"Initial management of shock in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further management considerations for children who have not improved after receiving 60",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of isotonic fluid include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with hemorrhagic shock should receive blood and require definitive treatment for the cause of hemorrhage. Packed red blood cells should be infused in 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      boluses. Delayed fluid resuscitation for traumatic hemorrhagic is not recommended for children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H10183078#H10183078\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Controlled hypotension'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For children with nonhemorrhagic hypovolemic shock, the amount of fluid loss may have been underestimated (as with burn injury) or there may be significant ongoing fluid loss (ie, from capillary leak with bowel obstruction). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44201?source=see_link&amp;anchor=H18#H18\">",
"       \"Emergency care of moderate and severe thermal burns in children\", section on 'Evaluation of burn injury'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Colloid administration may be an option for patients with decreased arterial volume related to low intravascular oncotic pressure (as in nephrotic syndrome or other causes of hypoalbuminemia). However, randomized trials and meta-analyses have failed to consistently demonstrate a difference in clinical outcomes for adults and children receiving colloid therapy for shock when compared to continue crystalloid infusion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Crystalloid versus colloid'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link&amp;anchor=H5#H5\">",
"       \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Colloid versus crystalloid'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vasoactive medications have",
"    <strong>",
"     no",
"    </strong>",
"    place in the treatment of isolated hypovolemic shock. These interventions do not address the underlying problem of inadequate circulating blood volume and may worsen tissue hypoxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, patients with septic shock who do require vasoactive medications often have concomitant hypovolemia and warrant aggressive fluid resuscitation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4634?source=see_link&amp;anchor=H19450206#H19450206\">",
"     \"Septic shock: Rapid recognition and initial resuscitation in children\", section on 'Intravenous fluid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H564789\">",
"    <span class=\"h2\">",
"     Glucose abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia should be corrected by rapid intravenous infusion of dextrose as described in the rapid overview (",
"    <a class=\"graphic graphic_table graphicRef83485 \" href=\"mobipreview.htm?31/43/32446\">",
"     table 4",
"    </a>",
"    ). Patients who should not have oral intake (eg, hemorrhagic shock from trauma) should have hypoglycemia corrected by intravenous dextrose infusion.",
"   </p>",
"   <p>",
"    For patients with stress hyperglycemia, treatment of the underlying condition typically suffices. As an example, among 72 critically ill patients, including trauma victims, with extreme stress hyperglycemia (blood glucose &gt;300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [16.7",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    glucose concentrations decreased to &le;150",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (8.3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in 67 percent within 48 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/4\">",
"     4",
"    </a>",
"    ]. Only eight of these patients received insulin or intravenous fluids without glucose to treat hyperglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ongoing management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once intravascular volume is restored and the patient's condition is stabilized, ongoing management is determined by the underlying condition. For children with hemorrhagic shock, the source of bleeding must be identified and controlled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/59/41912/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For those with nonhemorrhagic shock, the cause must be identified and treated (ie, relieving bowel obstruction with intussusception). Ongoing fluid therapy consists of repletion of deficit and ongoing losses and administration of maintenance requirements (",
"    <a class=\"graphic graphic_table graphicRef65412 \" href=\"mobipreview.htm?10/49/11035\">",
"     table 5",
"    </a>",
"    ). The sodium content of repletion fluid and the rate of correction are dependent upon the serum sodium (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of hypovolemia (dehydration) in children\", section on 'Therapy according to serum sodium'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who are normonatremic, the fluid deficit should be replaced with isotonic saline. The serum sodium concentration should not change substantially with repletion therapy, as sodium and water are given in proportion.",
"     </li>",
"     <li>",
"      Children with mild to moderate hyponatremia can be treated with isotonic saline alone, similar to normonatremic patients.",
"     </li>",
"     <li>",
"      With severe hyponatremia, correction of serum sodium at a rate of about 0.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      per hour is recommended to avoid the development of osmotic demyelination and irreversible neurologic injury. For patients with neurologic symptoms (ie, obtundation or active seizures), however, an initial goal of raising the serum sodium by 5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      over the first three to four hours by administering hypertonic saline (eg, 3 percent saline) is preferred because the risk of delayed therapy is greater than the risk of osmotic demyelination from overly rapid correction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Therapy according to serum sodium'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of the treatment of hyponatremia\", section on 'Rate of correction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The goals of therapy in children with hypovolemia and a serum sodium above 155",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      are correction of the volume deficit and gradual correction of the hypernatremia at a rate of less than 12",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      per day (less than 0.5",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"      per hour). Rapid correction of hypernatremia causes osmotic water movement into the brain, resulting in cerebral edema, which can lead to seizures, permanent neurologic damage, or death. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Therapy according to serum sodium'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fluid resuscitation in children with moderate to severe burns is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44201?source=see_link&amp;anchor=H22#H22\">",
"     \"Emergency care of moderate and severe thermal burns in children\", section on 'Fluid resuscitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with hypovolemic shock warrant inpatient admission and ongoing evaluation, monitoring, and treatment. Those who have traumatic hemorrhagic shock require management by a surgical team with expertise in pediatric trauma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H44#H44\">",
"     \"Trauma management: Approach to the unstable child\", section on 'Definitive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemic shock is characterized by inadequate tissue perfusion from decreased intravascular volume as the result of fluid loss",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inadequate fluid intake. Sources of volume loss include intravascular volume (as with hemorrhage, capillary leak, and third space losses from intraabdominal pathology [eg, pancreatitis, intussusception, small bowel obstruction]), extravascular fluid (as with vomiting, diarrhea, and osmotic diuresis), and insensible losses (moderate to severe burns). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among children in shock, compensatory mechanisms (ie, tachycardia, increased systemic vascular resistance, and increased cardiac contractility) typically maintain blood pressure until intravascular volume is decreased by 30 percent or more. Hypotension develops late and progresses rapidly to cardiovascular collapse. Clinical features can be used to estimate the amount of fluid lost (",
"      <a class=\"graphic graphic_table graphicRef76198 \" href=\"mobipreview.htm?13/5/13404\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68694 \" href=\"mobipreview.htm?33/47/34556\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An approach to rapidly identifying the cause of shock based upon clinical findings is provided in the algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef81356 \" href=\"mobipreview.htm?1/61/2000\">",
"       algorithm 1",
"      </a>",
"      ). Evaluation includes identification and stabilization of life-threatening conditions and identifying the source and amount of volume loss. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory evaluation may identify metabolic abnormalities (ie, hypoglycemia or hypernatremia) that require treatment. Hypoglycemia should be corrected by rapid intravenous infusion of dextrose as described in the rapid overview (",
"      <a class=\"graphic graphic_table graphicRef83485 \" href=\"mobipreview.htm?31/43/32446\">",
"       table 4",
"      </a>",
"      ). Children with hemorrhagic shock may require transfusion and should have samples sent to the blood bank for type and cross match.",
"     </li>",
"     <li>",
"      Successful management of children with hypovolemic shock requires identification and treatment of life-threatening conditions and the rapid initiation of aggressive fluid resuscitation:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cervical spine immobilization should be performed for children with traumatic hemorrhagic shock until a spinal fracture is ruled out. (See",
"      <a class=\"local\" href=\"#H564128\">",
"       'Airway and breathing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Airway management should include supplemental oxygen with an initial inspired concentration of 100 percent. Early positive pressure ventilation and intubation should be performed in patients with airway compromise or impending respiratory failure. A rapid overview provides the suggested approach to rapid sequence intubation in children (",
"      <a class=\"graphic graphic_table graphicRef51456 \" href=\"mobipreview.htm?17/26/17837\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H564128\">",
"       'Airway and breathing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sites of significant external hemorrhage require direct manual pressure to control bleeding (",
"      <a class=\"graphic graphic_figure graphicRef75556 \" href=\"mobipreview.htm?35/14/36078\">",
"       figure 2",
"      </a>",
"      ). In patients whose bleeding does not abate with direct pressure or who have a sharp foreign body at the site of bleeding or an amputation, compression at the nearest vascular pressure point provides an alternative means for hemorrhage control (",
"      <a class=\"graphic graphic_figure graphicRef75765 \" href=\"mobipreview.htm?28/16/28937\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Control of hemorrhage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate vascular access must be obtained for rapid infusion of fluid. Two peripheral intravenous catheters consisting of the largest size that can be reliably placed (22 to 24 gauge in newborns and infants, 18 to 20 gauge for older children) typically suffice. For children in shock, intraosseous cannulation should be performed if IV access cannot be established quickly. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Vascular access'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluid resuscitation includes the administration of isotonic crystalloid in 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      boluses, followed by evaluation of physiologic indicators of peripheral perfusion (blood pressure, quality of central and peripheral pulses, skin perfusion, mental status, and urine output). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fluid resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoglycemia should be corrected by rapid intravenous infusion of dextrose as described in the rapid overview (",
"      <a class=\"graphic graphic_table graphicRef83485 \" href=\"mobipreview.htm?31/43/32446\">",
"       table 4",
"      </a>",
"      ). For patients with stress hyperglycemia, treatment of the underlying condition typically suffices. (See",
"      <a class=\"local\" href=\"#H564789\">",
"       'Glucose abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who have not improved after receiving a total of 60",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic fluid should be evaluated for ongoing blood loss or other causes of shock. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fluid resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with nonhemorrhagic shock, the sodium content of repletion fluid and the rate of correction are dependent upon the serum sodium. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Ongoing management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Bell LM. Shock. In: Textbook of Pediatric Emergency Medicine, 6th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. p.46.",
"    </li>",
"    <li>",
"     World health statistics 2012. World Health Organization, WHO press, Geneva, Switzerland, 2012. file://www.who.int/gho/publications/world_health_statistics/2012/en/index.html (Accessed on November 13, 2012).",
"    </li>",
"    <li>",
"     Pediatric Advanced Life Support Provider Manual. Hazinski MF, Samson RA, Schexnayder SM (Eds). American Heart Association, Dallas, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41912/abstract/4\">",
"      Weiss SL, Alexander J, Agus MS. Extreme stress hyperglycemia during acute illness in a pediatric emergency department. Pediatr Emerg Care 2010; 26:626.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Surgeons Committee on Trauma. Shock. In: Advanced Trauma Life Support Course, 8th, American College of Surgeons, Chicago 2008. p.55.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/59/41912/abstract/6\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6389 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41912=[""].join("\n");
var outline_f40_59_41912=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ancillary data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564128\">",
"      Airway and breathing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Control of hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vascular access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Fluid resuscitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H564789\">",
"      Glucose abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ongoing management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6389\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6389|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?1/61/2000\" title=\"algorithm 1\">",
"      Undifferentiated pediatric shock algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6389|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/51/43834\" title=\"figure 1\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/14/36078\" title=\"figure 2\">",
"      Direct compression bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/16/28937\" title=\"figure 3\">",
"      Pressure points hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/23/7538\" title=\"figure 4\">",
"      Scalp lac hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/7/9331\" title=\"figure 5\">",
"      Pelvic binder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6389|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/5/13404\" title=\"table 1\">",
"      Pediatric signs of dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/47/34556\" title=\"table 2\">",
"      Classification of pediatric hemorrhage shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/26/17837\" title=\"table 3\">",
"      Rapid overview of rapid sequence intubation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/43/32446\" title=\"table 4\">",
"      Rapid overview for hypoglycemia in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/49/11035\" title=\"table 5\">",
"      Calculation maintenance fluid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/2/19497?source=related_link\">",
"      Child abuse: Injuries of the thorax; abdomen; retroperitoneum; and pelvis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/22/33124?source=related_link\">",
"      Closure of minor skin wounds with staples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37896?source=related_link\">",
"      Hemoptysis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/8/26762?source=related_link\">",
"      Initial management of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/51/40761?source=related_link\">",
"      Intraosseous infusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42901?source=related_link\">",
"      Physiology and classification of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/33/4634?source=related_link\">",
"      Septic shock: Rapid recognition and initial resuscitation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8057?source=related_link\">",
"      Vascular (venous) access for pediatric resuscitation and other pediatric emergencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_59_41913="Docetaxel: Drug information";
var content_f40_59_41913=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Docetaxel: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/15/12533?source=see_link\">",
"    see \"Docetaxel: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/50/14120?source=see_link\">",
"    see \"Docetaxel: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Docefrez&trade;;",
"     </li>",
"     <li>",
"      Taxotere&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Docetaxel for Injection;",
"     </li>",
"     <li>",
"      Taxotere&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F162093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Antimicrotubular;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Natural Source (Plant) Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Taxane Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F162057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with corticosteroids, beginning the day before docetaxel administration, (administer corticosteroids for 3 days) to reduce the severity of hypersensitivity reactions and fluid retention. Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer:",
"     </b>",
"     I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Locally-advanced or metastatic:",
"     </i>",
"     60-100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (as a single agent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Operable, node-positive (adjuvant treatment):",
"     </i>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks for 6 courses (in combination with doxorubicin and cyclophosphamide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Weekly administration (unlabeled dosing):",
"     </i>",
"     40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once a week (as a single agent) for 6 weeks followed by a 2-week rest, repeat until disease progression or unacceptable toxicity (Burstein, 2000)",
"     <b>",
"      or",
"     </b>",
"     35 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose once a week (in combination with trastuzumab) for 3 weeks followed by a 1-week rest; repeat until disease progression or unacceptable toxicity (Esteva, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer:",
"     </b>",
"     I.V. infusion: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (as a single agent or in combination with cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer:",
"     </b>",
"     I.V. infusion: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with prednisone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric adenocarcinoma:",
"     </b>",
"     I.V. infusion: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with cisplatin and fluorouracil)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sequential chemotherapy and chemoradiation (unlabeled dosing):",
"     </i>",
"     Induction: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 22 (in combination with cisplatin) for 2 cycles, followed by chemoradiation: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 5 weeks (in combination with cisplatin and radiation) (Ruhstaller, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Locally-advanced or metastatic disease (unlabeled dosing):",
"     </i>",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin) until disease progression or unacceptable toxicity up to a maximum of 8 cycles (Al-Batran, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Head and neck cancer:",
"     </b>",
"     I.V. infusion: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with cisplatin and fluorouracil) for 3 or 4 cycles, followed by radiation therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Breast cancer:",
"     </b>",
"     I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Locally-advanced or metastatic:",
"     </i>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (as combination therapy)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (as a single agent) every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Operable, node-positive (adjuvant treatment):",
"     </i>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks for 6 courses (in combination with doxorubicin and cyclophosphamide)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer (locally-advanced or metastatic), ovarian cancer (metastatic), head and neck cancer (recurrent and/or metastatic):",
"     </b>",
"     I.V. infusion: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (as combination therapy)",
"     <b>",
"      or",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (as a single agent) every 3 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer (hormone-refractory, metastatic):",
"     </b>",
"     I.V. infusion: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with prednisone or prednisolone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Unlabeled uses:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Bladder cancer, metastatic (unlabeled use):",
"     </b>",
"     I.V. infusion: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (as a single agent) (McCaffrey, 1997)",
"     <b>",
"      or",
"     </b>",
"     35 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 of a 21-day cycle (in combination with gemcitabine and cisplatin) for at least 6 cycles or until disease progression or unacceptable toxicity (Pectasides, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Esophageal cancer (unlabeled use):",
"     </b>",
"     I.V. infusion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Sequential chemotherapy and chemoradiation:",
"     </i>",
"     Induction: 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 22 (in combination with cisplatin) for 2 cycles, followed by chemoradiation: 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     weekly for 5 weeks (in combination with cisplatin and radiation) (Ruhstaller, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Definitive chemoradiation:",
"     </i>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 22 (in combination with cisplatin and radiation) for 1 cycle (Li, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Locally-advanced or metastatic disease:",
"     </i>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 3 weeks (in combination with cisplatin and fluorouracil) (Ajani, 2007; Van Cutsem, 2006)",
"     <b>",
"      or",
"     </b>",
"     50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 every 2 weeks (in combination with fluorouracil, leucovorin, and oxaliplatin) until disease progression or unacceptable toxicity up to a maximum of 8 cycles (Al-Batran, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ewing sarcoma, osteosarcoma (recurrent or progressive; unlabeled uses):",
"     </b>",
"     100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 8 of a 21-day cycle (in combination with gemcitabine) (Navid, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer (unlabeled use in U.S.):",
"     </b>",
"     I.V. infusion: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with carboplatin) (Markman, 2001)",
"     <b>",
"      or",
"     </b>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (in combination with carboplatin) (Vasey, 2004)",
"     <b>",
"      or",
"     </b>",
"     35 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 70 mg)  weekly for 3 weeks followed by a 1-week rest (in combination with carboplatin) (Kushner, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer, relapsed (unlabeled use):",
"     </b>",
"     I.V. infusion: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks (Smyth, 1994)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Soft tissue sarcoma (unlabeled use):",
"     </b>",
"     I.V. infusion: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 8 of a 3-week treatment cycle (in combination with gemcitabine and filgrastim or pegfilgrastim) (Leu, 2004; Maki, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Unknown-primary, adenocarcinoma (unlabeled use):",
"     </b>",
"     I.V. infusion: 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 3 weeks  (in combination with carboplatin) (Greco, 2000)",
"     <b>",
"      or",
"     </b>",
"     75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 8 of a 3-week treatment cycle (in combination with gemcitabine)  (Pouessel, 2004)",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 3-week treatment cycle (in combination with cisplatin) (Mukai, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Dosing adjustment for concomitant CYP3A4 inhibitors:",
"     </i>",
"     Avoid the concomitant use of strong CYP3A4 inhibitors with docetaxel. If concomitant use of a strong CYP3A4 inhibitor cannot be avoided, consider reducing the docetaxel dose by 50% (based on limited pharmacokinetic data).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing in obesity:",
"     </b>",
"     <i>",
"      ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:",
"     </i>",
"     When chemotherapy dosing is weight-based, utilize full weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F16148913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/50/14120?source=see_link\">",
"      see \"Docetaxel: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with corticosteroids, beginning the day before docetaxel administration, (administer corticosteroids for 3 days) to reduce the severity of hypersensitivity reactions and fluid retention. Details concerning dosing in combination regimens should also be consulted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Ewing sarcoma, osteosarcoma (recurrent or progressive; unlabeled uses):",
"     </b>",
"     Children &ge;8 years and Adolescents: I.V. infusion: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 8 of a 21-day cycle (in combination with gemcitabine) (Navid, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F162058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5527295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Renal excretion is minimal (~6%), therefore, the need for dosage adjustments for renal dysfunction is unlikely (Li, 2007).  Not removed by hemodialysis, may be administered before or after hemodialysis (Janus, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F162059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       U.S. labeling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Total bilirubin greater than the ULN, or AST and/or ALT &gt;1.5 times ULN concomitant with alkaline phosphatase &gt;2.5 times ULN: Use is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic impairment dosing adjustment specific for gastric adenocarcinoma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     AST/ALT &gt;2.5 to &le;5 times ULN and alkaline phosphatase &le;2.5 times ULN: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     AST/ALT &gt;1.5 to &le;5 times ULN and alkaline phosphatase &gt;2.5 to &le;5 times ULN: Administer 80% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     AST/ALT &gt;5 times ULN and /or alkaline phosphatase &gt;5 times ULN: Discontinue docetaxel",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Dosing recommendations when used as a single agent; dosage adjustment when used as part of combination therapy not provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AST and/or ALT &gt;1.5 times ULN and alkaline phosphatase &gt;2.5 times ULN: Reduce dose from 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin &gt;ULN and/or AST and ALT &gt; 3.5 times ULN associated with alkaline phosphatase &gt;6 times ULN: Avoid use unless strictly indicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       The following adjustments have also been used (Floyd, 2006):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases 1.6-6 times ULN: Administer 75% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &gt;6 times ULN: Use clinical judgment.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F162094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Toxicity includes febrile neutropenia, neutrophils &le;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;1 week, severe or cumulative cutaneous reactions; in nonsmall cell lung cancer, this may also include platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and other grade 3/4 nonhematologic toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer (single agent):",
"     </b>",
"     Patients dosed initially at 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     If the patient continues to experience these adverse reactions, the dosage should be reduced to 55 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     or therapy should be discontinued; discontinue for peripheral neuropathy &ge; grade 3. Patients initiated at 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     who do not develop toxicity may tolerate higher doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, adjuvant treatment (combination chemotherapy):",
"     </b>",
"     TAC regimen should be administered when neutrophils are &ge;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     . Patients experiencing febrile neutropenia should receive G-CSF in all subsequent cycles. Patients with persistent febrile neutropenia (while on G-CSF), patients experiencing severe/cumulative cutaneous reactions, moderate neurosensory effects (signs/symptoms) or grade 3 or 4 stomatitis should receive a reduced dose  (60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) of docetaxel. Discontinue therapy with persistent toxicities after dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Monotherapy: Patients dosed initially at 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     should have dose held until toxicity is resolved, then resume at 55 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; discontinue for peripheral neuropathy &ge; grade 3.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Combination therapy (with cisplatin): Patients dosed initially at 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     should have the docetaxel dosage reduced to 65 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in subsequent cycles; if further adjustment is required, dosage may be reduced to 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer:",
"     </b>",
"     Reduce dose to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; discontinue therapy if toxicities persist at lower dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gastric cancer, head and neck cancer:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Cisplatin may require dose reductions/therapy delays for peripheral neuropathy, ototoxicity, and/or nephrotoxicity. Patients experiencing febrile neutropenia, documented infection with neutropenia or neutropenia &gt;7 days should receive G-CSF in all subsequent cycles. For neutropenic complications despite G-CSF use, further reduce dose to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Dosing with neutropenic complications in subsequent cycles should be further reduced to 45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Patients who experience grade 4 thrombocytopenia should receive a dose reduction from 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .  Discontinue therapy for persistent toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Gastrointestinal toxicity for docetaxel in combination with cisplatin and fluorouracil for treatment of gastric cancer or head and neck cancer:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diarrhea, grade 3:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     First episode: Reduce fluorouracil dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Second episode: Reduce docetaxel dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diarrhea, grade 4:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     First episode: Reduce fluorouracil and docetaxel doses by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Second episode: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stomatitis, grade 3:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     First episode: Reduce fluorouracil dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Second episode: Discontinue fluorouracil for all subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Third episode: Reduce docetaxel dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Stomatitis, grade 4:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     First episode: Discontinue fluorouracil for all subsequent cycles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Second episode: Reduce docetaxel dose by 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Canadian labeling:",
"      </i>",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Toxicity includes febrile neutropenia, neutrophils &le;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     for &gt;1 week, severe or cumulative cutaneous reactions, or severe neurosensory symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients initially dosed at 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     : Reduce dose to 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; Patients initially dosed at 75 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     : Reduce dose to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Discontinue therapy for persistent toxicities after dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Breast cancer, adjuvant treatment (combination chemotherapy):",
"     </b>",
"     Patients experiencing febrile neutropenia should receive G-CSF in all subsequent cycles. Patients with persistent febrile neutropenia (while on G-CSF), patients experiencing severe/cumulative cutaneous reactions, severe neurosensory symptoms, or grade 3 or 4 stomatitis should receive a reduced dose (60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ). Discontinue therapy with persistent toxicities after dosage reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Concomitant use with capecitabine (treatment of metastatic breast cancer):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Grade 2 toxicities:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First episode: Interrupt therapy until resolution to &lt; grade 2, then resume docetaxel and capecitabine at previous dose; consider prophylactic measures if appropriate and/or possible",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second episode of same toxicity: Interrupt therapy until resolution to &lt; grade 2, then resume docetaxel at 55 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; capecitabine dose should be reduced by 25% of original dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Further episodes of same toxicity: Discontinue docetaxel; interrupt capecitabine until resolution to &lt; grade 2, then resume at 50% of original dose (third episode) or discontinue therapy altogether (fourth episode)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Grade 3 toxicities:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First episode: Occurring at time treatment is due: Interrupt docetaxel until resolution to &lt; grade 2 (maximum delay &le;2 weeks), then resume docetaxel at 55 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; reduce capecitabine dose to 75% of original dose; if no resolution to &lt; grade 2 within 2 weeks, discontinue docetaxel but may resume capecitabine at 75% of original dose after resolution to &lt; grade 2. Occurring between cycles and resolves to &lt; grade 2 by time of next treatment: Administer docetaxel at 55 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and reduce capecitabine dose to 75% of original dose; consider prophylactic measures if appropriate and/or possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Further episodes of same toxicity: Discontinue docetaxel; interrupt capecitabine until resolution to &lt; grade 2, then resume capecitabine at 50% of original dose (second episode) or discontinue therapy altogether (third episode)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Grade 4 toxicities: First episode: Discontinue docetaxel and capecitabine therapy or if deemed clinically necessary, capecitabine may be continued at 50% of original dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Docefrez&trade;: 20 mg, 80 mg [contains ethanol (in diluent), polysorbate 80 (in diluent); supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]: 20 mg/0.5 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Taxotere&reg;: 20 mg/mL [contains dehydrated ethanol 0.395 g/mL, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes  injection, powder for reconstitution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F162031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. infusion over 1-hour through nonsorbing polyethylene lined (non-DEHP) tubing; in-line filter is not necessary (the use of a filter during administration is not recommended by the manufacturer). Infusion should be completed within 4 hours of final preparation.",
"     <b>",
"      Note:",
"     </b>",
"     Premedication with corticosteroids for 3 days, beginning the day before docetaxel administration, is recommended to prevent hypersensitivity reactions and fluid retention (see Additional Information or Pharmacotherapy Pearls).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Irritant with vesicant-like properties; avoid extravasation. Assure proper needle or catheter position prior to administration. If extravasation occurs, stop infusion immediately and initiate appropriate extravasation management, including topical cooling for 15-20 minutes at least 4 times daily for 1-2 days (Polovich, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F162100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, amifostine, amikacin, aminophylline, ampicillin, ampicillin/sulbactam, anidulafungin, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, cefazolin, cefepime, cefotaxime, cefotetan, cefoxitin, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, clindamycin, dexamethasone sodium phosphate, dexrazoxane, diphenhydramine, dobutamine, dopamine, doripenem, doxycycline, droperidol, enalaprilat, famotidine, fluconazole, furosemide, gallium nitrate, ganciclovir, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hydrocortisone sodium succinate, hydromorphone, hydroxyzine, imipenem/cilastatin, leucovorin calcium, lorazepam, magnesium sulfate, mannitol, meperidine, meropenem, mesna, metoclopramide, metronidazole, minocycline, morphine, ondansetron, oxaliplatin, palonosetron, pemetrexed, piperacillin, piperacillin/tazobactam, potassium chloride, prochlorperazine edisylate, promethazine, ranitidine, sodium bicarbonate, sulfamethoxazole/trimethoprim, ticarcillin/clavulanate, tobramycin, vancomycin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B, doxorubicin liposome, methylprednisolone sodium succinate, nalbuphine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F162029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     U.S. labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Docefrez&trade;: Treatment of breast cancer (locally advanced/metastatic) after prior chemotherapy failure; treatment of nonsmall cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy; metastatic prostate cancer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Taxotere&reg;: Treatment of breast cancer (locally advanced/metastatic or adjuvant treatment of operable node-positive); locally-advanced or metastatic nonsmall cell lung cancer (NSCLC); hormone refractory, metastatic prostate cancer; advanced gastric adenocarcinoma; locally-advanced squamous cell head and neck cancer",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canadian labeling: Treatment of breast cancer (locally advanced/metastatic or adjuvant treatment of operable node-positive); locally-advanced or metastatic nonsmall cell lung cancer (NSCLC); hormone refractory, metastatic prostate cancer; recurrent and/or metastatic squamous cell head and neck cancer; treatment of metastatic ovarian cancer following failure of first-line or subsequent chemotherapy",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F162089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bladder cancer (metastatic), ovarian cancer, cervical cancer (recurrent), esophageal cancer, small cell lung cancer (relapsed), soft tissue sarcoma, Ewing&rsquo;s sarcoma, osteosarcoma, and unknown-primary adenocarcinoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F162103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DOCEtaxel may be confused with cabazitaxel, PACLitaxel",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Taxotere&reg; may be confused with Taxol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Multiple concentrations: Docetaxel is available as a one-vial formulation at concentrations of 10 mg/mL (generic formulation) and 20 mg/mL (concentrate; Taxotere&reg;), and as a lyophilized powder (Docefrez&trade;) which is reconstituted (with provided diluent) to 20 mg/0.8 mL (20 mg vial) or 24 mg/mL (80 mg vial). Docetaxel was previously available as a two-vial formulation (a concentrated docetaxel solution vial and a diluent vial) resulting in a reconstituted concentration of 10 mg/mL. The two-vial formulation has been discontinued by the manufacturer. Admixture errors have occurred due to the availability of various docetaxel concentrations.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F162091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported for docetaxel monotherapy; frequency may vary depending on diagnosis, dose, liver function, prior treatment, and premedication. The incidence of adverse events was usually higher in patients with elevated liver function tests.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Fluid retention (13% to 60%; dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Neurosensory events (20% to 58%; including neuropathy), fever (31% to 35%), neuromotor events (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (56% to 76%), cutaneous events (20% to 48%), nail disorder (11% to 41%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis (19% to 53%; severe 1% to 8%), diarrhea (23% to 43%; severe: 5% to 6%), nausea (34% to 42%), vomiting (22% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (84% to 99%; grade 4: 75% to 86%; nadir (median): 7 days, duration (severe neutropenia): 7 days; dose dependent), leukopenia (84% to 99%; grade 4: 32% to 44%), anemia (65% to 94%; dose dependent; grades 3/4: 8% to 9%), thrombocytopenia (8% to 14%; grade 4: 1%; dose dependent), febrile neutropenia (6% to 12%; dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (4% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (53% to 66%; severe 13% to 18%), myalgia (3% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary events (41%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (1% to 34%; dose dependent), hypersensitivity (1% to 21%; with premedication 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Left ventricular ejection fraction decreased (prostate cancer: 10%; metastatic breast cancer: 8%), hypotension (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Taste perversion (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Bilirubin increased (9%), alkaline phosphatase increased (4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Infusion-site reactions (4%, including hyperpigmentation, inflammation, redness, dryness, phlebitis, extravasation, swelling of the vein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular and skeletal: Arthralgia (3% to 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Epiphora associated with canalicular stenosis (&le;77% with weekly administration; &le;1% with every 3-week administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute myeloid leukemia (AML), acute respiratory distress syndrome (ARDS), anaphylactic shock, arrhythmia, ascites, atrial fibrillation, atrial flutter, AV block, bleeding episodes, bradycardia, bronchospasm, cardiac tamponade, chest pain, chest tightness, colitis, conjunctivitis, constipation, cutaneous lupus erythematosus, deep vein thrombosis, dehydration, disseminated intravascular coagulation (DIC), drug fever, duodenal ulcer, dyspnea, dysrhythmia, ECG abnormalities, erythema multiforme, esophagitis, gastrointestinal hemorrhage, gastrointestinal obstruction, gastrointestinal perforation, hand and foot syndrome, hearing loss, heart failure, hepatitis, hypertension, ileus, interstitial pneumonia, ischemic colitis, lacrimal duct obstruction, loss of consciousness (transient), MI, multiorgan failure, myelodysplastic syndrome, myocardial ischemia, neutropenic enterocolitis, neutropenic typhlitis, ototoxicity, pericardial effusion, pleural effusion, pruritus, pulmonary edema, pulmonary embolism, pulmonary fibrosis, radiation pneumonitis, radiation recall, renal failure, renal insufficiency, scleroderma-like changes, seizure, sepsis, sinus tachycardia, Stevens-Johnson syndrome, syncope, toxic epidermal necrolysis, tachycardia, thrombophlebitis, unstable angina, visual disturbances (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F162034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Severe hepatic impairment; pregnancy; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F162018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Patients with an absolute neutrophil count &lt;1500/mm",
"      <sup>",
"       3",
"      </sup>",
"      should not receive docetaxel.",
"     </b>",
"     Platelets should recover to &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     prior to treatment. The dose-limiting toxicity is neutropenia. Patients with increased liver function tests experienced more episodes of neutropenia with a greater number of severe infections. Monitor blood counts and liver function tests frequently; dose reduction or therapy discontinuation may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cutaneous reactions: Cutaneous reactions, including erythema (with edema) and desquamation, have been reported; may require dose reduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid retention:",
"     <b>",
"      [U.S. Boxed Warning]: Severe fluid retention, characterized by pleural effusion (requiring immediate drainage), ascites, peripheral edema (poorly tolerated), dyspnea at rest, cardiac tamponade, and weight gain (2-15 kg) has been reported.",
"     </b>",
"     The incidence and severity of fluid retention increases sharply at cumulative doses &ge;400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     . Patients should be premedicated with a corticosteroid (starting 1 day prior to administration) to prevent or reduce the severity of fluid retention. Closely monitor patients with existing effusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions:",
"     <b>",
"      [U.S. Boxed Warning]: Severe hypersensitivity reactions, characterized by generalized rash/erythema, hypotension, bronchospasms, or anaphylaxis may occur; do not administer to patients with a history of severe hypersensitivity to docetaxel or polysorbate 80.",
"     </b>",
"     Minor reactions including flushing or localized skin reactions may also occur. Observe for hypersensitivity, especially with the first 2 infusions. Discontinue for severe reactions; do not rechallenge if severe. Patients should be premedicated with a corticosteroid (starting 1 day prior to administration) to prevent or reduce the severity of hypersensitivity reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurosensory symptoms: Dosage adjustment is recommended with severe neurosensory symptoms (paresthesia, dysesthesia, pain); persistent symptoms may require discontinuation. Reversal of symptoms may be delayed after discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Treatment-related acute myeloid leukemia or myelodysplasia occurred in patients receiving docetaxel in combination with anthracyclines and/or cyclophosphamide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Treatment-related mortality:",
"     <b>",
"      [U.S. Boxed Warning]: Patients with abnormal liver function, those receiving higher doses, and patients with nonsmall cell lung cancer and a history of prior treatment with platinum derivatives who receive single-agent docetaxel at a dose of 100 mg/m",
"      <sup>",
"       2",
"      </sup>",
"      are at higher risk for treatment-related mortality.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weakness: Fatigue and weakness (may be severe) have been reported; symptoms may last a few days up to several weeks. In patients with progressive disease, weakness may be associated with a decrease in performance status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Avoid use in patients with bilirubin exceeding upper limit of normal (ULN) or AST and/or ALT &gt;1.5 times ULN in conjunction with alkaline phosphatase &gt;2.5 times ULN.",
"     </b>",
"     Patients with abnormal liver function are at increased risk of treatment-related adverse events, including grade 4 neutropenia, neutropenic fever, infections, and sever thrombocytopenia, stomatitis, skin toxicity or toxic death. Obtain liver function tests prior to each treatment cycle. Canadian labeling contraindicates use in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Excipient: Contains polysorbate 80, which is associated with hypersensitivity reactions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F162087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antineoplastic Agents (Anthracycline, Systemic): Taxane Derivatives may enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May increase the serum concentration of DOCEtaxel. Management: Avoid this combination whenever possible.  If this combination must be used, consider using a reduced docetaxel dose, and/or increase monitoring for evidence of serious docetaxel toxicity (e.g., neutropenia, mucositis, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Platinum Derivatives: May enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: May increase the serum concentration of DOCEtaxel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F162048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to GI irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease docetaxel levels).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F162024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F162037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. An",
"     <i>",
"      ex vivo",
"     </i>",
"     human placenta perfusion model illustrated that docetaxel crossed the placenta at term. Placental transfer was low and affected by the presence of albumin; higher albumin concentrations resulted in lower docetaxel placental transfer (Berveiller,  2012). Women of childbearing potential should avoid becoming pregnant. A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F162065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F162038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if docetaxel is excreted into breast milk. Due to the potential for serious adverse reactions in nursing the infant, the decision to discontinue docetaxel or to discontinue breast-feeding should take into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (DOCEtaxel Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/0.5 mL (0.5 mL): $365.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/2 mL (2 mL): $1460.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Taxotere Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/mL (1 mL): $518.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/2 mL (2 mL): $1976.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/4 mL (4 mL): $2075.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (DOCEtaxel Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/2 mL (2 mL): $222.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/8 mL (8 mL): $888.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg/16 mL (16 mL): $1758.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Docefrez Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $322.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (1): $1290.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F162026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, liver function tests, bilirubin, alkaline phosphatase, renal function; monitor for hypersensitivity reactions, neurosensory symptoms, gastrointestinal toxicity (eg, diarrhea, stomatitis), cutaneous reactions, fluid retention, epiphora, and canalicular stenosis",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Belotaxel (KP);",
"     </li>",
"     <li>",
"      Brexel (ID);",
"     </li>",
"     <li>",
"      Daxotel (PH, TH);",
"     </li>",
"     <li>",
"      Dexotel (IN);",
"     </li>",
"     <li>",
"      Docetere (ID);",
"     </li>",
"     <li>",
"      Doci (PH);",
"     </li>",
"     <li>",
"      Dotaxel (KP);",
"     </li>",
"     <li>",
"      Hentaxel (PH);",
"     </li>",
"     <li>",
"      Isotera (TW);",
"     </li>",
"     <li>",
"      Monotaxel (KP);",
"     </li>",
"     <li>",
"      Oncotaxel (SG);",
"     </li>",
"     <li>",
"      Pacancer (KP);",
"     </li>",
"     <li>",
"      Taxelo (KP);",
"     </li>",
"     <li>",
"      Taxomed (PE);",
"     </li>",
"     <li>",
"      Taxotere (AR, AT, AU, BD, BE, BF, BG, BJ, BO, BR, CH, CI, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, GT, HK, HN, ID, IE, IL, IT, JP, KE, KP, LR, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PR, PT, PY, RU, SC, SD, SE, SG, SK, SL, SN, SV, TH, TN, TR, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Taxozen (KP);",
"     </li>",
"     <li>",
"      Tedocad (BG);",
"     </li>",
"     <li>",
"      Texot (AR);",
"     </li>",
"     <li>",
"      Tyxan (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F162017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Docetaxel promotes the assembly of microtubules from tubulin dimers, and inhibits the depolymerization of tubulin which stabilizes microtubules in the cell. This results in inhibition of DNA, RNA, and protein synthesis. Most activity occurs during the M phase of the cell cycle.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F162033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exhibits linear pharmacokinetics at the recommended dosage range",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive extravascular distribution and/or tissue binding; V",
"     <sub>",
"      dss",
"     </sub>",
"     : 113 L (mean steady state)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~94% to 97%, primarily to alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein, albumin, and lipoproteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; oxidation via CYP3A4 to metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: ~11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~75%, &lt;8% as unchanged drug); urine (~6%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ajani JA, Fodor MD, Tjulandin SA, et al, &ldquo;Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(24):5660-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/16110025/pubmed\" id=\"16110025\" target=\"_blank\">",
"        16110025",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ajani JA, Moiseyenko VM, Tjulandin S, et al, &ldquo;Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Cancer Adenocarcinoma: The V-325 Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(22):3205-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/17664467/pubmed\" id=\"17664467\" target=\"_blank\">",
"        17664467",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Al-Batran SE, Hartmann JT, Hofheinz R, et al, \"Biweekly Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) for Patients With Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction: A Phase II Trial of the Arbeitsgemeinschaft Internistische Onkologie,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(11):1882-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/18669868/pubmed\" id=\"18669868\" target=\"_blank\">",
"        18669868",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berveiller P, Vinot C, Mir O, et al, \"Comparative Transplacental Transfer of Taxanes Using the Human Perfused Cotyledon Placental Model,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2012, 207(6):514.e1-514.e7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/23174392/pubmed\" id=\"23174392\" target=\"_blank\">",
"        23174392",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blohmer JU, Schmid P, Hilfrich J, et al, &ldquo;Epirubicin and Cyclophosphamide Versus Epirubicin and Docetaxel as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomised Phase III Trial,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1430-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/20089562/pubmed\" id=\"20089562\" target=\"_blank\">",
"        20089562",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burstein HJ, Manola J, Younger J, et al, &ldquo;Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2000, 18(6):1212-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/10715290 /pubmed\" id=\"10715290 \" target=\"_blank\">",
"        10715290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Day FL, Leong T, Ngan S, et al, &ldquo;Phase I Trial of Docetaxel, Cisplatin and Concurrent Radical Radiotherapy in Locally Advanced Oesophageal Cancer,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2011, 104(2):265-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/21157450/pubmed\" id=\"21157450\" target=\"_blank\">",
"        21157450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Esteva FJ, Valero V, Booser D, et al, &ldquo;Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2-Overexpressing Metastatic Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(7):1800-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/11919237/pubmed\" id=\"11919237\" target=\"_blank\">",
"        11919237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia AA, Blessing JA, Vaccarell L, et al, &ldquo;Phase II Clinical Trial of Docetaxel in Refractory Squamous Cell Carcinoma of the Cervix:  A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 2007, 30(4):428-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/17762444/pubmed\" id=\"17762444\" target=\"_blank\">",
"        17762444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greco FA, Erland JB, Morrissey LH, et al, &ldquo;Carcinoma of Unknown Primary Site: Phase II Trials With Docetaxel Plus Cisplatin or Carboplatin,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2000, 11(2):211-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/10761758/pubmed\" id=\"10761758\" target=\"_blank\">",
"        10761758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(13):1553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/22473167/pubmed\" id=\"22473167\" target=\"_blank\">",
"        22473167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner DM, Connor JP, Sanchez F, et al, &ldquo;Weekly Docetaxel and Carboplatin for Recurrent Ovarian and Peritoneal Cancer: A Phase II Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2007, 105(2):358-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/17258800/pubmed\" id=\"17258800\" target=\"_blank\">",
"        17258800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leu KM, Ostruszka LJ, Shewach D, et al, &ldquo;Laboratory and Clinical Evidence of Synergistic Cytotoxicity of Sequential Treatment With Gemcitabine Followed by Docetaxel in the Treatment of Sarcoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(9):1706-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/15117993/pubmed\" id=\"15117993\" target=\"_blank\">",
"        15117993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li QQ, Liu MZ, Hu YH, et al, &ldquo;Definitive Concomitant Chemoradiotherapy With Docetaxel and Cisplatin in Squamous Esophageal Carcinoma,&rdquo;",
"      <i>",
"       Dis Esophagus",
"      </i>",
"      , 2010, 23(3):253-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/19732130/pubmed\" id=\"19732130\" target=\"_blank\">",
"        19732130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li YF, Fu S, Hu W, et al, &ldquo;Systemic Anticancer Therapy in Gynecological Cancer Patients With Renal Dysfunction,&rdquo;",
"      <i>",
"       Int J Gynecol Cancer",
"      </i>",
"      , 2007, 7(4):739-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/17309673/pubmed\" id=\"17309673\" target=\"_blank\">",
"        17309673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maki RG, Wathen JK, Patel SR, et al, &ldquo;Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(19):2755-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/17602081/pubmed\" id=\"17602081\" target=\"_blank\">",
"        17602081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Markman M, Kennedy A, Webster K, et al, &ldquo;Combination Chemotherapy With Carboplatin and Docetaxel in the Treatment of Cancers of the Ovary and Fallopian Tube and Primary Carcinoma of the Peritoneum,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(7):1901-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/11283121/pubmed\" id=\"11283121\" target=\"_blank\">",
"        11283121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mavroudis D, Papakotoulas P, Ardavanis A, et al, &ldquo;Randomized Phase III Trial Comparing Docetaxel Plus Epirubicin Versus Docetaxel Plus Capecitabine as First-Line Treatment in Women With Advanced Breast Cancer,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(1):48-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/19906761/pubmed\" id=\"19906761\" target=\"_blank\">",
"        19906761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McCaffrey JA, Hilton S, Mazumdar M, et al, &ldquo;Phase II Trial of Docetaxel in Patients With Advanced or Metastatic Transitional-Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(5):1853-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/ 9164195/pubmed\" id=\" 9164195\" target=\"_blank\">",
"        9164195",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mukai H, Katsumata N, Ando M, et al, &ldquo;Safety and Efficacy of a Combination of Docetaxel and Cisplatin in Patients With Unknown Primary Cancer,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 2010, 33(1):32-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/19786850/pubmed\" id=\"19786850\" target=\"_blank\">",
"        19786850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muro K, Hamaguchi T, Ohtsu A, et al, &ldquo;A Phase II Study of Single-Agent Docetaxel in Patients With Metastatic Esophageal Cancer,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(6):955-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/15151954/pubmed\" id=\"15151954\" target=\"_blank\">",
"        15151954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Navid F, Willert JR, McCarville MB, et al, &ldquo;Combination of Gemcitabine and Docetaxel in the Treatment of Children and Young Adults With Refractory Bone Sarcoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(2):419-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/18484657/pubmed\" id=\"18484657\" target=\"_blank\">",
"        18484657",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pectasides D, Glotsos J, Bountouroglou N, et al, &ldquo;Weekly Chemotherapy With Docetaxel, Gemcitabine and Cisplatin in Advanced Transitional Cell Urothelial Cancer: A Phase II Trial,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2002, 13(2):243-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/11886001/pubmed\" id=\"11886001\" target=\"_blank\">",
"        11886001",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pointreau Y, Garaud P, Chapet S, et al, &ldquo;Randomized Trial of Induction Chemotherapy With Cisplatin and 5-Fluorouracil With or Without Docetaxel forLlarynx Preservation,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2009, 101(7):498-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/19318632/pubmed\" id=\"19318632\" target=\"_blank\">",
"        19318632",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polovich M, Whitford JN and Olsen M,",
"      <i>",
"       Chemotherapy and Biotherapy Guidelines and Recommendations for Practice",
"      </i>",
"      , 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Posner MR, Glisson B, Frenette G, et al, &ldquo;Multicenter Phase I-II Trial of Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy for Patients With Locally Advanced Squamous Cell Cancer of the Head and Neck,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(4):1096-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/11181674/pubmed\" id=\"11181674\" target=\"_blank\">",
"        11181674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Posner MR, Hershock DM, Blajman CR, et al, &ldquo;Cisplatin and Fluorouracil Alone or With Docetaxel in Head and Neck Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(17):1705-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/17960013/pubmed\" id=\"17960013\" target=\"_blank\">",
"        17960013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pouessel D, Culine S, Becht C, et al, &ldquo;Gemcitabine and Docetaxel as Front-Line Chemotherapy in Patients With Carcinoma of an Unknown Primary Site,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 100(6):1257-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/15022294/pubmed\" id=\"15022294\" target=\"_blank\">",
"        15022294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ruhstaller T, Widmer L, Schuller JC, et al, &ldquo;Multicenter Phase II Trial of Preoperative Induction Chemotherapy Followed by Chemoradiation With Docetaxel and Cisplatin for Locally Advanced Esophageal Carcinoma (SAKK 75/02),&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2009, 20(9):1522-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/19465425/pubmed\" id=\"19465425\" target=\"_blank\">",
"        19465425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schrijvers D, Van Herpen C, Kerger J, et al, &ldquo;Docetaxel, Cisplatin and 5-Fluorouracil in Patients With Locally Advanced Unresectable Head and Neck Cancer: A Phase I-II Feasibility Study,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2004, 15(4):638-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/15033673/pubmed\" id=\"15033673\" target=\"_blank\">",
"        15033673",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smyth JF, Smith IE, Sessa C, et al, &ldquo;Activity of Docetaxel (Taxotere) in Small Cell Lung Cancer. The Early Clinical Trials Group of the EORTC,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1994, 30A(8):1058-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/7654428 /pubmed\" id=\"7654428 \" target=\"_blank\">",
"        7654428",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Van Cutsem E, Moiseyenko VM, Tjulandin S, et al, &ldquo;Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil as First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(31):4991-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/17075117/pubmed\" id=\"17075117\" target=\"_blank\">",
"        17075117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vasey PA, Jayson GC, Gordon A, et al, &ldquo;Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2004, 96(22):1682-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/15547181/pubmed\" id=\"15547181\" target=\"_blank\">",
"        15547181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vermorken JB, Remenar E, van Herpen C, et al, &ldquo;Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 357(17):1695-704.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?40/59/41913/abstract-text/17960012/pubmed\" id=\"17960012\" target=\"_blank\">",
"        17960012",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9381 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-F0C764AA00-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41913=[""].join("\n");
var outline_f40_59_41913=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708706\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162052\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162053\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162093\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162057\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16148913\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162058\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5527295\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162059\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162094\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162028\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162014\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162031\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162100\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162029\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162089\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162103\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162091\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162034\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162018\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162087\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162022\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162048\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162024\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162037\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162065\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162038\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323117\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162026\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869377\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162017\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162033\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9381\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9381|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/15/12533?source=related_link\">",
"      Docetaxel: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/50/14120?source=related_link\">",
"      Docetaxel: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_59_41914="Anaplastic large cell lymphoma skin 3";
var content_f40_59_41914=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83092%7EDERM%2F83091%7EDERM%2F83089%7EDERM%2F83095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83092%7EDERM%2F83091%7EDERM%2F83089%7EDERM%2F83095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous anaplastic large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multicentric primary cutaneous anaplastic large cell lymphoma of skin on the face of a 47-year-old man.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous anaplastic large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multicentric primary cutaneous anaplastic large cell lymphoma on the chest of a 36-year-old man.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary cutaneous anaplastic large cell lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Primary cutaneous anaplastic large cell lymphoma on the neck of a 24-year-old man.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Dermatology Online Atlas, www.dermis.net. Copyright &copy; 2012. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Secondary skin lesions in Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41914=[""].join("\n");
var outline_f40_59_41914=null;
var title_f40_59_41915="Diabetes screening tests PI";
var content_f40_59_41915=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diabetes screening tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Glucose level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fasting glucose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal",
"       </td>",
"       <td>",
"        70 to 99",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pre-diabetes",
"       </td>",
"       <td>",
"        100 to 125",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes",
"       </td>",
"       <td>",
"        126 or higher on at least 2 tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Glucose tolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal",
"       </td>",
"       <td>",
"        Below 140",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pre-diabetes",
"       </td>",
"       <td>",
"        140 to 199",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        Diabetes",
"       </td>",
"       <td>",
"        200 or higher on at least 2 tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        A1C percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        A1C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Normal",
"       </td>",
"       <td>",
"        Below 5.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pre-diabetes",
"       </td>",
"       <td>",
"        5.7 to 6.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes",
"       </td>",
"       <td>",
"        6.5 or higher on at least 2 tests",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Pre-diabetes is a term doctor or nurses use as a warning. People with pre-diabetes do not yet have diabetes, but they are at increased risk of getting it.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41915=[""].join("\n");
var outline_f40_59_41915=null;
var title_f40_59_41916="Calcium blockers post MI";
var content_f40_59_41916=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74199&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Calcium channel blockers do not change mortality after acute MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 200px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A meta-analysis of controlled trials of calcium channel blockers in postinfarction patients failed to show any effect on mortality, although the agents that reduce heart rate, particularly verapamil, showed a trend toward an improved survival while nifedipine, which increases heart rate, showed a trend toward an increased mortaltiy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Held PH, Yusuf S. In: Cardiovascular Pharmacology and Therapeutics, Singh BN, Dzau V, Vanhoutte PM, Woosley RL (Eds), Churchill Livingstone, New York, 1993, p. 525.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41916=[""].join("\n");
var outline_f40_59_41916=null;
var title_f40_59_41917="Contents: Cosmetic dermatology";
var content_f40_59_41917=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Cosmetic dermatology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Cosmetic dermatology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Botulinum toxin",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/20/14665\">",
"           Botulinum toxin for cosmetic indications: Treatment of specific sites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/15/22778\">",
"           Overview of botulinum toxin for cosmetic indications",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Laser and light therapy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?1/36/1610\">",
"           Ablative laser resurfacing for skin rejuvenation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/9/9370\">",
"           Laser and light therapy for cutaneous hyperpigmentation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/47/17146\">",
"           Laser and light therapy for cutaneous vascular lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/6/42089\">",
"           Nonablative skin resurfacing for skin rejuvenation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/53/22360\">",
"           Principles of laser and intense pulsed light for cutaneous lesions",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?22/54/23400\">",
"           Photoaging",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/9/37014\">",
"           Removal of unwanted hair",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Soft tissue fillers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/26/27049\">",
"           Injectable soft tissue fillers: Overview of clinical use",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/26/26024\">",
"           Injectable soft tissue fillers: Permanent agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?23/23/23930\">",
"           Injectable soft tissue fillers: Semipermanent agents",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-AAB6386E1E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_59_41917=[""].join("\n");
var outline_f40_59_41917=null;
var title_f40_59_41918="Revascular silent ischemia";
var content_f40_59_41918=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Revascularization improves outcome in silent ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 458px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel: Among 558 patients with silent ischemia who were randomly assigned to angina guided drug therapy, drug therapy guided by silent ischemia, or revascularization, mortality was significantly reduced mortality with revascularization compared to the other two options. There was no difference between angina and ischemic guided strategies. Bottom panel: The two year rate of death or myocardial infarction (MI) was significantly lower only when revascularization was compared to angina guided therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Davies RF, Goldberg D, Forman S, et al. For the ACIP Investigators, Circulation 1997; 95:2037.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41918=[""].join("\n");
var outline_f40_59_41918=null;
var title_f40_59_41919="PTC before hepaticojejunostomy";
var content_f40_59_41919=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F69335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F69335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete transection of the common bile duct after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percutaneous transhepatic cholangiogram demonstrating complete transection of the common bile duct and dilation of the biliary tree. This patient was treated with a hepaticojejunostomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_59_41919=[""].join("\n");
var outline_f40_59_41919=null;
